{"48910397cf6fc5867fffc8e2bf24d56701da41ee": [["I. INTRODUCTIONIn many advanced economies, productivity growth has been declining since the late 1990s and is now at historically low levels (Adler et al., 2017) .", [["many advanced economies", "TREATMENT", 18, 41], ["productivity growth", "PROBLEM", 43, 62], ["advanced", "OBSERVATION_MODIFIER", 23, 31], ["economies", "OBSERVATION", 32, 41], ["declining", "OBSERVATION_MODIFIER", 72, 81]]], ["1 The recent COVID-19 crisis has generated concern that productivity may further decline (Mauro and Syverson, 2020 and Baldwin and Weder di Mauro, 2020).", [["The recent COVID", "TEST", 2, 18]]], ["2 From a theoretical standpoint, the recessions-total factor productivity nexus is ambiguous \u00e0 priori.", [["the recessions", "PROBLEM", 33, 47], ["total factor productivity nexus", "PROBLEM", 48, 79], ["recessions", "OBSERVATION", 37, 47]]], ["On the one hand, in models of knowledge accumulation (e.g., Grossman and Helpman, 1991) , a fall in the proportion of the labor force dedicated to research and development following a negative output shock could lead to a long-lasting negative impact on the level of productivity.", [["shock", "DISEASE", 200, 205], ["a fall", "PROBLEM", 90, 96], ["a negative output shock", "PROBLEM", 182, 205], ["a long-lasting negative impact", "PROBLEM", 220, 250]]], ["On the other hand, in models of Schumpeter's creative destruction (e.g. Caballero and Hammour, 1994) , recessions can have a cleansing economic effect by eliminating inefficient firms, consequently generating higher productivity and GDP growth.", [["GDP", "CHEMICAL", 233, 236], ["GDP", "CHEMICAL", 233, 236], ["GDP", "SIMPLE_CHEMICAL", 233, 236], ["Schumpeter's creative destruction", "PROBLEM", 32, 65], ["recessions", "PROBLEM", 103, 113], ["a cleansing economic effect", "TREATMENT", 123, 150], ["inefficient firms", "PROBLEM", 166, 183], ["higher productivity and GDP growth", "PROBLEM", 209, 243], ["destruction", "OBSERVATION", 54, 65], ["higher", "OBSERVATION_MODIFIER", 209, 215], ["productivity", "OBSERVATION_MODIFIER", 216, 228]]], ["3 In particular, aggregate productivity can be affected by recessions in two separate manners: i) by means of their impact on productivity 1 A recent paper by Crats and Mills (2020) conjectures that the UK productivity slowdown is unprecedented in the past 250 years and reflects a combination of adverse circumstances, namely, a financial crisis, a weakening impact of ICT and impending Brexit.", [["a financial crisis", "PROBLEM", 328, 346], ["impending Brexit", "PROBLEM", 378, 394]]], ["2 For a recent paper relating productivity and the COVID-19 shock using industry-level data in Canada see Blit (2020) .", [["shock", "DISEASE", 60, 65], ["the COVID-19 shock", "TREATMENT", 47, 65]]], ["3 Theoretically, the different set of constraints forced by recessions should close business of the least productivity firms and rise aggregate productivity (Petrosky-Nadeau, 2013).", [["recessions", "PROBLEM", 60, 70], ["rise aggregate productivity", "PROBLEM", 129, 156], ["least", "OBSERVATION_MODIFIER", 100, 105], ["productivity", "OBSERVATION_MODIFIER", 106, 118], ["firms", "OBSERVATION_MODIFIER", 119, 124], ["rise", "OBSERVATION_MODIFIER", 129, 133], ["aggregate productivity", "OBSERVATION", 134, 156]]], ["Relatedly, we also have the \"pit-stop\" view of recessions in which these correspond to periods of reduced profits and times during which restructuring can be done due to temporarily lower opportunity costs (Aghion and Saint-Paul, 1998 ).", [["recessions", "PROBLEM", 47, 57], ["reduced profits", "PROBLEM", 98, 113], ["recessions", "OBSERVATION", 47, 57], ["reduced", "OBSERVATION_MODIFIER", 98, 105], ["profits", "OBSERVATION", 106, 113]]], ["More recently, Gropp et al. (2020) assessed the cleansing effects of the Global Financial Crises looking at US regions.", [["the cleansing effects", "TREATMENT", 44, 65], ["the Global Financial Crises", "PROBLEM", 69, 96], ["Global", "OBSERVATION_MODIFIER", 73, 79], ["Financial Crises", "OBSERVATION", 80, 96]]], ["4 The effect through sectoral reallocation is not clear, since labor can move between various lowand high-productivity sectors, with an ambiguous net effect on productivity.", [["labor", "PROBLEM", 63, 68], ["sectoral", "OBSERVATION_MODIFIER", 21, 29], ["not", "UNCERTAINTY", 46, 49], ["clear", "OBSERVATION", 50, 55], ["net effect", "OBSERVATION", 146, 156]]], ["Counter-cyclical reallocation takes place when input factor reallocation during a downturn leads to less productive jobs being destroyed and labor moving into more productive uses (Mortensen and Pissarides, 1994) .", [["cyclical reallocation", "TREATMENT", 8, 29], ["labor", "PROBLEM", 141, 146]]], ["Pro-cyclical reallocation occurs when more productive industries are disproportionately affected by recessions, for example due to credit constraints (Barlevy, 2003) .", [["Pro-cyclical reallocation", "PROBLEM", 0, 25]]], ["Therefore, the extent to which recessions impact total factor productivity (TFP) is ultimately an empirical question.", [["TFP", "CHEMICAL", 76, 79], ["total factor productivity", "PROBLEM", 49, 74], ["recessions", "OBSERVATION_MODIFIER", 31, 41]]], ["Against this background, this paper offers new empirical evidence on the impact of recessionary periods on productivity, including through reallocation.I. INTRODUCTIONWhile several studies have looked into this issue, we improve upon previous studies in two ways.I. INTRODUCTIONFirst, we construct a new measure of TFP growth adjusted for time-varying unobserved use in capital and labor.", [["TFP", "CHEMICAL", 315, 318], ["TFP", "CHEMICAL", 315, 318], ["TFP", "SIMPLE_CHEMICAL", 315, 318], ["several studies", "TEST", 173, 188], ["previous studies", "TEST", 234, 250], ["TFP growth", "PROBLEM", 315, 325], ["labor", "PROBLEM", 382, 387]]], ["5 Correcting for unobserved input factor utilization is crucial to accurately assess the development of aggregate TFP across the different phases of the business cycle and in the aftermath of recessions.", [["TFP", "CHEMICAL", 114, 117], ["TFP", "CHEMICAL", 114, 117], ["TFP", "SIMPLE_CHEMICAL", 114, 117], ["aggregate TFP", "PROBLEM", 104, 117], ["recessions", "PROBLEM", 192, 202], ["recessions", "OBSERVATION", 192, 202]]], ["Second, we explore the role of within-and between-sectors productivity.4Our analysis is carried out in three stages.", [["Our analysis", "TEST", 72, 84]]], ["First, we calculate time series of cyclicallyadjusted TFP growth following the method used by Basu et al. (2006) The rest of the paper is organized in the following way.", [["TFP", "CHEMICAL", 54, 57], ["TFP", "CHEMICAL", 54, 57], ["TFP", "SIMPLE_CHEMICAL", 54, 57], ["cyclicallyadjusted TFP growth", "TREATMENT", 35, 64], ["organized", "OBSERVATION", 138, 147]]], ["Section 2 discusses the empirical methodology and presents the data used to evaluate the impact of recessions on productivity.A. Utilization Adjusted Total Factor ProductivityWe follow the approach of Basu et al. (2006) and Fernald (2014a Fernald ( , 2014b to estimate a measure of TFP growth adjusted for time-varying unobserved use in capital and labor, based on sectoral data.", [["TFP", "CHEMICAL", 282, 285], ["TFP", "SIMPLE_CHEMICAL", 282, 285], ["recessions", "PROBLEM", 99, 109], ["TFP growth", "PROBLEM", 282, 292], ["labor", "PROBLEM", 349, 354], ["sectoral data", "TEST", 365, 378], ["recessions", "OBSERVATION", 99, 109]]], ["Correcting for unobserved input factor utilization is crucial to accurately assess the development of aggregate TFP growth across the different phases of the business cycle and, specifically, in the aftermath of recessions-the focus of the paper.A. Utilization Adjusted Total Factor ProductivityThe approach consists in the following.", [["TFP", "CHEMICAL", 112, 115], ["TFP", "CHEMICAL", 112, 115], ["TFP", "SIMPLE_CHEMICAL", 112, 115], ["aggregate TFP growth", "PROBLEM", 102, 122], ["different phases", "OBSERVATION_MODIFIER", 134, 150]]], ["Let's start assuming that the production function of each industry i is given by:A. Utilization Adjusted Total Factor Productivitywhere \u202b\u0723\u202c ,\u0be7 is TFP of industry i at time t; K and L denote the capital stock and labor inputs, respectively; the symbol \u0de9 denote utilization-adjusted capital and labor effort:A. Utilization Adjusted Total Factor ProductivityJ o u r n a l P r e -p r o o f 6 where \u202b\u0737\u0725\u202c ,\u0be7 and \u202b\u0727\u202c ,\u0be7 denote capacity utilization for capital stock and labor effort, respectively.A. Utilization Adjusted Total Factor ProductivityFollowing Basu et al. (2006) , the production function \u202b\u0728(\u202c ) is assumed to be homogeneous of degree \u07d9 in total inputs.", [["K", "TEST", 175, 176], ["the capital stock", "TREATMENT", 190, 207], ["labor inputs", "PROBLEM", 212, 224], ["capital stock", "TREATMENT", 445, 458], ["labor effort", "PROBLEM", 463, 475], ["capital stock", "OBSERVATION", 445, 458]]], ["Assuming a cost minimization objective, output growth is related to the growth of input factors for each industry i as follows:A. Utilization Adjusted Total Factor Productivitywhere dy refers to the growth rate of gross output and \u202b\u0742\u0750\u0740\u202c is TFP growth. dx is the observed input growth-defined as \u202b\u0754\u0740\u202c = s , \u0740\u0747 + s , \u0740\u0748 + s , \u0740\u0749 \u0b67 ; and du is the unobserved input utilization growth-defined as \u202b\u0751\u0740\u202c = s , \u202b\u0751\u073f\u0740\u202c + s , \u0740\u0741 .A. Utilization Adjusted Total Factor ProductivityThe aggregate TFP growth is then obtained as the aggregate Solow residual minus the aggregate input utilization:A. Utilization Adjusted Total Factor ProductivityThis implies that TFP growth is equal to the Solow residual when there are no changes in utilization.", [["TFP", "CHEMICAL", 240, 243], ["TFP", "CHEMICAL", 482, 485], ["TFP", "CHEMICAL", 647, 650], ["TFP", "CHEMICAL", 647, 650], ["TFP", "SIMPLE_CHEMICAL", 240, 243], ["dx", "GENE_OR_GENE_PRODUCT", 252, 254], ["TFP", "SIMPLE_CHEMICAL", 482, 485], ["TFP", "SIMPLE_CHEMICAL", 647, 650], ["input factors", "PROTEIN", 82, 95], ["output growth", "PROBLEM", 40, 53], ["Total Factor Productivitywhere dy", "TREATMENT", 151, 184], ["gross output", "TEST", 214, 226], ["TFP growth", "PROBLEM", 240, 250], ["utilization growth", "TEST", 362, 380], ["\u202b\u0751\u073f\u0740\u202c", "TEST", 403, 408], ["Utilization", "TEST", 422, 433], ["Total Factor Productivity", "PROBLEM", 443, 468], ["The aggregate TFP growth", "TEST", 468, 492], ["TFP growth", "PROBLEM", 647, 657], ["changes in utilization", "PROBLEM", 707, 729], ["du", "ANATOMY", 335, 337], ["no", "UNCERTAINTY", 704, 706]]], ["The aggregate Solow residual and input utilization are calculated as weighted sums of industry Solow residuals and utilization measures, respectively:A. Utilization Adjusted Total Factor Productivity7 \u202b\u0753\u202c is the industry' proportion in gross output, and \u202b\u0749\u074f\u202c is the proportion of input payments in total costs.A. Utilization Adjusted Total Factor ProductivityThe measure of cyclically-adjusted TFP is computed for an unbalanced sample of 18 advanced economies from 1970 to 2014, using EU KLEMS sectoral data for 24 industries.", [["utilization measures", "TREATMENT", 115, 135], ["an unbalanced sample", "TEST", 414, 434], ["gross output", "OBSERVATION", 236, 248]]], ["6 Table 1 shows some descriptive statistics of the measure of cyclically-adjusted TFP computed for the countries in our sample and it compares with those of the standard Solow residual.", [["TFP", "CHEMICAL", 82, 85], ["TFP", "SIMPLE_CHEMICAL", 82, 85]]], ["Figure 1 plots, for each of the 18 countries in the sample, the time profile of both measures (additional summary statistics are provided in Table A1 ).A. Utilization Adjusted Total Factor Productivity[insert Table 1] [insert Figure 1 ]Decomposition into within and between componentsUsing the method proposed by McMillan and Rodrick\u00b4s (2014), we decompose aggregate TFP is into two components: the within part; and the between part.", [["TFP", "CHEMICAL", 367, 370], ["TFP", "CHEMICAL", 367, 370], ["TFP", "SIMPLE_CHEMICAL", 367, 370], ["Total Factor Productivity[insert Table 1] [insert Figure 1 ]Decomposition", "TREATMENT", 176, 249]]], ["7 Specifically, we decompose the cumulative changes in TFP between time t and time t+k as follows: 6 The list of countries in our sample is the following: Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Japan, Korea, the Netherlands, Portugal, Spain, the UK and the US.", [["TFP", "CHEMICAL", 55, 58], ["TFP", "CHEMICAL", 55, 58], ["TFP", "SIMPLE_CHEMICAL", 55, 58], ["the cumulative changes in TFP", "PROBLEM", 29, 58], ["the US", "TEST", 310, 316]]], ["7 Labor reallocation from low-to high-productivity activities was a key determinant of productivity growth in several regions of the world.", [["Labor reallocation", "PROBLEM", 2, 20]]], ["The impact of structural reallocation on aggregate productivity was studied by Carree (2003) for the advanced economies, Olley and Pakes (1996) and Timmer and Szirmai (2000) for the Asian region, , Bartelsman is the logarithm of the cyclically-adjusted TFP of sector i in country j, and \u202b\u0753\u202c ,,\u0be7 is the proportion of sector i's value added.", [["TFP", "CHEMICAL", 253, 256], ["the advanced economies", "TREATMENT", 97, 119], ["structural", "OBSERVATION_MODIFIER", 14, 24], ["reallocation", "OBSERVATION_MODIFIER", 25, 37]]], ["8 The first right-hand side term corresponds to the within component while the second right-hand side term corresponds to the between component.B. MethodologyThe econometric method we use to assess the dynamic impact of economic downturns on productivity is Jord\u00e0\u00b4s (2005) local projection approach.", [["right-hand", "ANATOMY", 12, 22], ["right-hand", "ANATOMY", 86, 96], ["right", "ANATOMY_MODIFIER", 12, 17], ["hand side", "ANATOMY_MODIFIER", 18, 27], ["component", "OBSERVATION_MODIFIER", 59, 68], ["right", "ANATOMY_MODIFIER", 86, 91], ["hand", "ANATOMY", 92, 96]]], ["The method allows us to trace the dynamics of productivity growth in the aftermath of recessions, controlling for pre-crisis trends in productivity.", [["productivity growth", "PROBLEM", 46, 65], ["recessions", "PROBLEM", 86, 96], ["recessions", "OBSERVATION", 86, 96]]], ["The following equation is estimated for each horizon k = 0, . . ., 5:B. Methodologywhere \u202b\u0754\u202c \u0be7\u0b3e, \u2212 \u202b\u0754\u202c \u0be7\u0b3f\u0b35, is the cumulative change of the dependent variable (cyclically-adjusted TFP and its within and between components) for country j; \u07d9 and \u07db \u0be7 denote respectively country and time fixed effects.", [["the cumulative change", "PROBLEM", 111, 132]]], ["D is a dummy variable taking the value of one at the beginning of a recession period (see definition below), and zero otherwise.", [["a dummy variable", "PROBLEM", 5, 21]]], ["Additional controls include: (i) two lags of past output growth, (ii) two lags of recession dates, (iii) country-specific trends.", [["past output growth", "PROBLEM", 45, 63], ["recession dates", "PROBLEM", 82, 97]]], ["Note that 8 These weights are those we also use to compute our aggregate measure of cyclically-adjusted TFP growth.B. MethodologyWeights are given by \u202b\u0753\u202c /(1 \u2212 \u202b\u0749\u074f\u202c ) in which \u202b\u0753\u202c is the industry's proportion in gross output, and \u202b\u0749\u074f\u202c is the proportion of input payments in total costs (Basu et al, 2006) .", [["TFP", "CHEMICAL", 104, 107], ["TFP", "CHEMICAL", 104, 107], ["TFP", "SIMPLE_CHEMICAL", 104, 107]]], ["The industry's proportion in aggregate value added is used as weight in TFP growth rates.", [["TFP", "CHEMICAL", 72, 75], ["TFP", "SIMPLE_CHEMICAL", 72, 75], ["weight in TFP growth rates", "TEST", 62, 88]]], ["9 at some forecasting horizon k, the dependent variable may already be affected by the recession, even though the variable measuring recession is set equal to zero.", [["the variable measuring recession", "PROBLEM", 110, 142], ["recession", "OBSERVATION", 87, 96], ["variable", "OBSERVATION_MODIFIER", 114, 122], ["recession", "OBSERVATION", 133, 142]]], ["In such case, the effect of the recession on the dependent variable will be absorbed by the fixed effects rather than being (Table A2) .", [["the recession", "PROBLEM", 28, 41], ["the fixed effects", "PROBLEM", 88, 105], ["recession", "OBSERVATION", 32, 41]]], ["We then extend the analysis to consider alternative recessions and compare their productivity effects with those associated with deep recessions.III. EMPIRICAL RESULTSBefore moving to the analysis on the effect of deep recessions on cyclically-adjusted TFP it is useful to examine the effects on aggregate output and input of production.", [["TFP", "CHEMICAL", 253, 256], ["TFP", "CHEMICAL", 253, 256], ["TFP", "SIMPLE_CHEMICAL", 253, 256], ["the analysis", "TEST", 15, 27], ["alternative recessions", "TREATMENT", 40, 62], ["deep recessions", "PROBLEM", 129, 144], ["the analysis", "TEST", 184, 196], ["deep recessions", "PROBLEM", 214, 229], ["TFP", "TREATMENT", 253, 256], ["aggregate output", "TEST", 296, 312], ["deep recessions", "OBSERVATION", 129, 144]]], ["To do so we estimate equation (6), alternatively using as dependent variables total output, employment and capital.", [["dependent variables total output", "PROBLEM", 58, 90]]], ["EMPIRICAL RESULTSDigging further, the results-not shown but available from the authors upon requestindicate that following past deep recessions economic activity has re-allocated from high productivity sectors such as information and communication, wholesale and retail trade and transportation to low-productivity sectors such as social services and real estate (results not shown but available upon request).", [["past deep recessions economic activity", "PROBLEM", 123, 161]]], ["These results are consistent with evidence provided in other papers suggesting that high productivity sectors tend to contract more during downturns (e.g.Types of RecessionsResults shown until now provided evidence that, on average, deep recessions have a significant and persistent negative effect on TFP.", [["TFP", "CHEMICAL", 302, 305], ["TFP", "CHEMICAL", 302, 305], ["TFP", "SIMPLE_CHEMICAL", 302, 305], ["high productivity sectors", "PROBLEM", 84, 109], ["deep recessions", "PROBLEM", 233, 248], ["persistent negative effect on TFP", "PROBLEM", 272, 305], ["consistent with", "UNCERTAINTY", 18, 33], ["significant", "OBSERVATION_MODIFIER", 256, 267], ["persistent", "OBSERVATION_MODIFIER", 272, 282], ["negative", "OBSERVATION", 283, 291]]], ["However, such losses are likely to vary with the severity and the type of recessions (real vs. financial crisis).", [["the severity", "PROBLEM", 45, 57], ["recessions (real vs. financial crisis", "PROBLEM", 74, 111], ["recessions", "OBSERVATION", 74, 84]]], ["In the first exercise, we construct a dummy that takes value 1 for all the other \"non-severe\" recessions identified in Blanchard et al.Types of Recessions(2015).", [["non-severe\" recessions", "PROBLEM", 82, 104], ["recessions", "OBSERVATION", 94, 104], ["Recessions", "OBSERVATION", 144, 154]]], ["In the second analysis, we consider, severe recessions that coincided with financial crises-for this purpose, we rely on the financial crisis database constructed by Laeven and Valencia (2018).", [["the second analysis", "TEST", 3, 22], ["severe recessions", "PROBLEM", 37, 54], ["financial crises", "PROBLEM", 75, 91], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["recessions", "OBSERVATION", 44, 54]]], ["9 The results for normal recessions are displayed in Figure 5 .", [["recessions", "OBSERVATION", 25, 35]]], ["In contrast, to deep recessions, normal recessions have not statistically significantly effects on TFP and its components.", [["TFP", "CHEMICAL", 99, 102], ["TFP", "CHEMICAL", 99, 102], ["TFP", "SIMPLE_CHEMICAL", 99, 102], ["TFP", "TEST", 99, 102], ["deep", "ANATOMY_MODIFIER", 16, 20], ["recessions", "OBSERVATION", 21, 31], ["normal recessions", "OBSERVATION", 33, 50], ["not statistically significantly effects", "OBSERVATION_MODIFIER", 56, 95]]], ["This 9 There is a large body of literature on the output costs of a financial crises.", [["a financial crises", "PROBLEM", 66, 84], ["large", "OBSERVATION_MODIFIER", 18, 23], ["body", "OBSERVATION_MODIFIER", 24, 28], ["output", "OBSERVATION_MODIFIER", 50, 56], ["financial crises", "OBSERVATION", 68, 84]]], ["Most seem to agree that these crises have severe output effects- Romer and Romer (2017) [insert Figure 5 ]Types of RecessionsIn Figure 6 , we present the results for deep recessions that are also financial crises.", [["these crises", "PROBLEM", 24, 36], ["severe output effects", "PROBLEM", 42, 63], ["RecessionsIn Figure", "TREATMENT", 115, 134], ["deep recessions", "PROBLEM", 166, 181], ["deep recessions", "OBSERVATION", 166, 181]]], ["Overall, the results do not point to any systematic difference between \"real\" deep recessions and \"financial\" deep recession-if any the results for deep financial crises are less precisely estimated because of fewer episodes.", [["\"real\" deep recessions", "PROBLEM", 71, 93], ["\"financial\" deep recession", "PROBLEM", 98, 124], ["deep financial crises", "PROBLEM", 148, 169], ["fewer episodes", "PROBLEM", 210, 224], ["deep recessions", "OBSERVATION", 78, 93], ["deep recession", "OBSERVATION", 110, 124]]], ["In both cases, TFP declines by about 3 percent in the medium-term, with the persistent effect mostly driven by sectoral re-allocation (the between component).Types of Recessions[insert Figure 6 ]Country GroupingsWe examine whether the previous cross-country average effects mask considerable heterogeneity across countries.", [["TFP", "CHEMICAL", 15, 18], ["TFP", "CHEMICAL", 15, 18], ["TFP", "SIMPLE_CHEMICAL", 15, 18], ["the persistent effect", "PROBLEM", 72, 93], ["Recessions", "PROBLEM", 167, 177], ["persistent", "OBSERVATION_MODIFIER", 76, 86], ["effect", "OBSERVATION", 87, 93], ["Recessions", "OBSERVATION", 167, 177]]], ["In particular, given that several studies found that the allocation of resources worsened in southern Europe in the last two decades (e.g., Reis To address this issue, we re-estimate equation (6) alternatively including as control variables credit growth, the current account balance (in percent of GDP) and the debt-to-GDP ratio.", [["GDP", "CHEMICAL", 299, 302], ["GDP", "CHEMICAL", 320, 323], ["GDP", "SIMPLE_CHEMICAL", 299, 302], ["GDP", "SIMPLE_CHEMICAL", 320, 323], ["several studies", "TEST", 26, 41], ["GDP", "TEST", 299, 302], ["the debt", "TEST", 308, 316], ["GDP ratio", "TEST", 320, 329]]], ["Figure 7 shows the results for the cyclically-adjusted TFP within and between components and confirms that such augmentations of the vector of controls do not change the basic thrust of our results;Country Groupingsthat is, TFP goes down following a deep recession and most of that fall is due to between-sector reallocation of input factors.Country Groupings[insert Figure 8 ]IV.", [["TFP", "CHEMICAL", 55, 58], ["TFP", "CHEMICAL", 224, 227], ["TFP", "CHEMICAL", 55, 58], ["TFP", "CHEMICAL", 224, 227], ["TFP", "SIMPLE_CHEMICAL", 55, 58], ["input factors", "PROTEIN", 328, 341], ["TFP", "TEST", 55, 58], ["the vector of controls", "TREATMENT", 129, 151], ["TFP", "TEST", 224, 227], ["a deep recession", "PROBLEM", 248, 264], ["IV", "TREATMENT", 377, 379]]], ["CONCLUSION AND POLICY IMPLICATIONSIn many advanced economies, productivity growth has been declining since the late 1990s and is now at historically low levels.", [["many advanced economies", "TREATMENT", 37, 60], ["productivity growth", "PROBLEM", 62, 81]]], ["There are worries that the current COVID-19 crisis may exacerbate this negative trend and further reduce total factor productivity growth.", [["the current COVID", "TEST", 23, 40], ["total factor productivity growth", "PROBLEM", 105, 137]]], ["While there are different channels through which the current and past crises can lead to permanent J o u r n a l P r e -p r o o f 14 productivity losses, one often-cited factor is through sectoral reallocation-that is, the betweensector component of productivity that reflect reallocation of resources across sectors.IV. CONCLUSION AND POLICY IMPLICATIONSThis paper provided new evidence on the potential impact of the COVID-19 crisis by examining the effect of past deep recessions on a newly constructed measure of cyclicality adjusted TFP.", [["TFP", "CHEMICAL", 538, 541], ["TFP", "CHEMICAL", 538, 541], ["TFP", "SIMPLE_CHEMICAL", 538, 541], ["productivity losses", "PROBLEM", 133, 152], ["IV", "TREATMENT", 317, 319], ["the COVID", "TEST", 415, 424], ["past deep recessions", "PROBLEM", 462, 482], ["different", "OBSERVATION_MODIFIER", 16, 25], ["channels", "OBSERVATION_MODIFIER", 26, 34], ["deep recessions", "OBSERVATION", 467, 482]]], ["We find that deep recessions are not only associated with a persistent decline in output and its input of production, but also with permanent TFP losses.", [["TFP", "CHEMICAL", 142, 145], ["TFP", "CHEMICAL", 142, 145], ["TFP", "SIMPLE_CHEMICAL", 142, 145], ["deep recessions", "PROBLEM", 13, 28], ["a persistent decline in output", "PROBLEM", 58, 88], ["permanent TFP losses", "PROBLEM", 132, 152], ["deep recessions", "OBSERVATION", 13, 28], ["persistent", "OBSERVATION_MODIFIER", 60, 70], ["decline", "OBSERVATION", 71, 78], ["output", "OBSERVATION_MODIFIER", 82, 88]]], ["In particular, we find that cyclically-adjusted TFP strongly decline in the aftermath of deep recessions with the amplitude of the effect lying between 3-4 percent after 3-5 years.", [["TFP", "CHEMICAL", 48, 51], ["TFP", "CHEMICAL", 48, 51], ["TFP", "SIMPLE_CHEMICAL", 48, 51], ["TFP strongly decline", "PROBLEM", 48, 68], ["deep recessions", "PROBLEM", 89, 104], ["deep recessions", "OBSERVATION", 89, 104]]], ["This effect comes from both the within and between components of TFP growth, but sectoral reallocation (the between effect) explains most of the medium-term decline in productivity.IV. CONCLUSION AND POLICY IMPLICATIONSWill the COVID-19 lead to similar losses?", [["TFP", "CHEMICAL", 65, 68], ["TFP", "CHEMICAL", 65, 68], ["TFP", "SIMPLE_CHEMICAL", 65, 68], ["TFP growth", "PROBLEM", 65, 75], ["the medium-term decline", "PROBLEM", 141, 164], ["IV", "TREATMENT", 181, 183], ["the COVID", "TEST", 224, 233], ["TFP", "OBSERVATION_MODIFIER", 65, 68], ["growth", "OBSERVATION_MODIFIER", 69, 75], ["sectoral", "OBSERVATION_MODIFIER", 81, 89]]], ["The crisis will surely lead to some sectoral reallocation from tourism, restaurants and other services that require in-person contact to sectors such as communication and IT.", [["The crisis", "PROBLEM", 0, 10], ["crisis", "OBSERVATION", 4, 10]]], ["But the effect on aggregate productivity will much depend on the level of productivity of each of these sectors, which may vary across countries.IV. CONCLUSION AND POLICY IMPLICATIONSMuch will also depend on the ability of policies to soften the persistence of the crisis and to reduce scarring effects.", [["aggregate productivity", "PROBLEM", 18, 40], ["IV", "TREATMENT", 145, 147], ["the crisis", "PROBLEM", 261, 271], ["scarring effects", "PROBLEM", 286, 302], ["scarring", "OBSERVATION", 286, 294]]], ["In this context, stimulating demand through fiscal and monetary policy and ensuring flow of credit to household and business would be key to mitigate the initial cost of the crisis.", [["monetary policy", "TREATMENT", 55, 70], ["the crisis", "PROBLEM", 170, 180]]], ["Significant fiscal stimulus on high-return investment will be also needed to sustain the recovery and should be complemented with structural reforms aimed at improving efficiency and help ensure resources are reallocated appropriately.", [["Significant fiscal stimulus", "PROBLEM", 0, 27], ["fiscal stimulus", "OBSERVATION", 12, 27]]]], "5c1a42461f3b042befd880ace8ce30dcfa9d4a17": [["highest-priority societal goal of mitigating the morbidity and mortality associated with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["acute respiratory syndrome coronavirus", "DISEASE", 106, 144], ["severe acute respiratory syndrome coronavirus", "SPECIES", 99, 144], ["SARS-CoV-2", "SPECIES", 148, 158], ["the morbidity", "PROBLEM", 45, 58], ["the novel severe acute respiratory syndrome coronavirus", "PROBLEM", 89, 144], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["acute", "OBSERVATION_MODIFIER", 106, 111], ["respiratory syndrome", "OBSERVATION", 112, 132]]]], "70ab834ceb629b547fe26f96c2bf13bb6f267d39": [["Dear Editor,We read with great interest the study by Singh et al., 1 in which the authors have shown the impact of obesity on the 30-day composite outcomes, death or intubation, in patients with coronavirus disease ).", [["obesity", "DISEASE", 115, 122], ["death", "DISEASE", 157, 162], ["coronavirus disease", "DISEASE", 195, 214], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["the study", "TEST", 40, 49], ["obesity", "PROBLEM", 115, 122], ["death", "PROBLEM", 157, 162], ["intubation", "TREATMENT", 166, 176], ["coronavirus disease", "PROBLEM", 195, 214], ["obesity", "OBSERVATION", 115, 122], ["coronavirus disease", "OBSERVATION", 195, 214]]], ["They also demonstrated higher risks of complications with increasing grades of obesity.", [["obesity", "DISEASE", 79, 86], ["complications", "PROBLEM", 39, 52], ["obesity", "PROBLEM", 79, 86], ["complications", "OBSERVATION", 39, 52], ["obesity", "OBSERVATION", 79, 86]]], ["However, there are a few concerns that merit further exploration.Dear Editor,First, the prevalence of fatty liver disease in the propensity-matched obese cohort was 5%.Dear Editor,However, multiple previous studies in patients with obesity have shown the prevalence to vary from 50% to 90%, and increasing trends with increasing body mass index (BMI).", [["fatty liver", "ANATOMY", 102, 113], ["body", "ANATOMY", 329, 333], ["fatty liver disease", "DISEASE", 102, 121], ["obesity", "DISEASE", 232, 239], ["liver", "ORGAN", 108, 113], ["patients", "ORGANISM", 218, 226], ["body", "ORGANISM_SUBDIVISION", 329, 333], ["patients", "SPECIES", 218, 226], ["further exploration", "TEST", 45, 64], ["fatty liver disease", "PROBLEM", 102, 121], ["multiple previous studies", "TEST", 189, 214], ["obesity", "PROBLEM", 232, 239], ["increasing body mass index", "PROBLEM", 318, 344], ["few", "OBSERVATION_MODIFIER", 21, 24], ["fatty", "OBSERVATION", 102, 107], ["liver", "ANATOMY", 108, 113], ["disease", "OBSERVATION", 114, 121], ["obese", "OBSERVATION", 148, 153], ["obesity", "OBSERVATION", 232, 239], ["increasing", "OBSERVATION_MODIFIER", 295, 305], ["mass", "OBSERVATION", 334, 338]]], ["2, 3 Patients with non-alcoholic fatty liver disease (NAFLD) may have an accelerated rate of progression to severe COVID-19.", [["non-alcoholic fatty liver", "ANATOMY", 19, 44], ["non-alcoholic fatty liver disease", "DISEASE", 19, 52], ["NAFLD", "DISEASE", 54, 59], ["COVID", "DISEASE", 115, 120], ["COVID-19", "CHEMICAL", 115, 123], ["Patients", "ORGANISM", 5, 13], ["liver", "ORGAN", 39, 44], ["Patients", "SPECIES", 5, 13], ["non-alcoholic fatty liver disease", "PROBLEM", 19, 52], ["an accelerated rate of progression", "PROBLEM", 70, 104], ["severe COVID", "PROBLEM", 108, 120], ["non-alcoholic", "OBSERVATION_MODIFIER", 19, 32], ["fatty", "OBSERVATION", 33, 38], ["liver", "ANATOMY", 39, 44], ["disease", "OBSERVATION", 45, 52], ["severe", "OBSERVATION_MODIFIER", 108, 114]]], ["4 Thus, estimating the true prevalence of NAFLD in such a large population, and evaluating its impact on the outcomes, would help in understanding the implications of COVID-19 in patients with obesity.Dear Editor,In the propensity-matched cohort, 368/8112 patients died in the obese cohort (140 and 158 with stage 2 and 3 obesity, respectively).", [["NAFLD", "DISEASE", 42, 47], ["obesity", "DISEASE", 193, 200], ["obesity", "DISEASE", 322, 329], ["COVID-19", "GENE_OR_GENE_PRODUCT", 167, 175], ["patients", "ORGANISM", 179, 187], ["patients", "ORGANISM", 256, 264], ["patients", "SPECIES", 179, 187], ["patients", "SPECIES", 256, 264], ["NAFLD", "PROBLEM", 42, 47], ["COVID", "TREATMENT", 167, 172], ["obesity", "PROBLEM", 193, 200], ["stage 2 and 3 obesity", "PROBLEM", 308, 329], ["NAFLD", "OBSERVATION", 42, 47], ["large", "OBSERVATION_MODIFIER", 58, 63], ["population", "OBSERVATION", 64, 74], ["obesity", "OBSERVATION", 193, 200], ["obese", "OBSERVATION", 277, 282]]], ["As estimated from the available results, the number of patients who died in the subgroup of stage 1 obesity (3006 cases and controls) in the propensity-matched cohort would be 70 (2.3%) and 90 (3.0%), respectively.", [["obesity", "DISEASE", 100, 107], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["stage 1 obesity", "PROBLEM", 92, 107], ["obesity", "OBSERVATION", 100, 107]]], ["These facts interestingly suggest lower mortality rates in patients with stage 1 obesity as compared to high-risk non-obese comparable controls.", [["obesity", "DISEASE", 81, 88], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["lower mortality rates", "PROBLEM", 34, 55], ["stage 1 obesity", "PROBLEM", 73, 88], ["lower", "OBSERVATION_MODIFIER", 34, 39], ["mortality", "OBSERVATION", 40, 49], ["obesity", "OBSERVATION", 81, 88]]], ["In another study of more than 17 million patients, stage 1 obesity was associated with an increased risk {Hazard ratio 1.05 (1.0-1.11)} of mortality when adjusted for other risk factors.", [["obesity", "DISEASE", 59, 66], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["another study", "TEST", 3, 16], ["stage 1 obesity", "PROBLEM", 51, 66], ["an increased risk", "PROBLEM", 87, 104], ["Hazard ratio", "TEST", 106, 118], ["other risk factors", "PROBLEM", 167, 185], ["obesity", "OBSERVATION", 59, 66], ["increased", "OBSERVATION_MODIFIER", 90, 99]]], ["5 Whether obesity influences the overall outcomes only after a particular threshold of BMI needs to be further evaluated.", [["obesity", "DISEASE", 10, 17], ["obesity", "PROBLEM", 10, 17], ["a particular threshold of BMI", "PROBLEM", 61, 90], ["obesity", "OBSERVATION", 10, 17]]], ["Also, it J o u r n a l P r e -p r o o f would be interesting to analyze whether obesity was an independent predictor of poor outcomes, using a regression analysis in the entire COVID-19 cohort.Dear Editor,The authors matched the two cohorts for multiple risk factors for mortality; however, the severity of COVID-19 at presentation, which is an important determinant of outcomes, was not matched.", [["obesity", "DISEASE", 80, 87], ["obesity", "PROBLEM", 80, 87], ["a regression analysis", "TEST", 141, 162], ["the entire COVID", "TREATMENT", 166, 182], ["COVID", "TEST", 307, 312]]], ["An unequal distribution of patients with greater severity of pneumonia at presentation between the groups could have impacted the outcomes.", [["pneumonia", "DISEASE", 61, 70], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["pneumonia", "PROBLEM", 61, 70], ["unequal", "OBSERVATION_MODIFIER", 3, 10], ["distribution", "OBSERVATION_MODIFIER", 11, 23], ["greater severity", "OBSERVATION_MODIFIER", 41, 57], ["pneumonia", "OBSERVATION", 61, 70]]], ["Other important factors, such as glycemic control, cardiac injury, differences in pharmacotherapy for COVID, and drugs for comorbidities like metformin, statins, aspirin, NSAIDs, might affect the overall outcomes in COVID-19.", [["cardiac", "ANATOMY", 51, 58], ["cardiac injury", "DISEASE", 51, 65], ["COVID", "DISEASE", 102, 107], ["metformin", "CHEMICAL", 142, 151], ["statins", "CHEMICAL", 153, 160], ["aspirin", "CHEMICAL", 162, 169], ["NSAIDs", "CHEMICAL", 171, 177], ["metformin", "CHEMICAL", 142, 151], ["statins", "CHEMICAL", 153, 160], ["aspirin", "CHEMICAL", 162, 169], ["cardiac", "ORGAN", 51, 58], ["metformin", "SIMPLE_CHEMICAL", 142, 151], ["statins", "SIMPLE_CHEMICAL", 153, 160], ["aspirin", "SIMPLE_CHEMICAL", 162, 169], ["NSAIDs", "SIMPLE_CHEMICAL", 171, 177], ["glycemic control", "TREATMENT", 33, 49], ["cardiac injury", "PROBLEM", 51, 65], ["pharmacotherapy", "TREATMENT", 82, 97], ["COVID", "TREATMENT", 102, 107], ["drugs", "TREATMENT", 113, 118], ["comorbidities", "PROBLEM", 123, 136], ["metformin", "TREATMENT", 142, 151], ["statins", "TREATMENT", 153, 160], ["aspirin", "TREATMENT", 162, 169], ["NSAIDs", "TREATMENT", 171, 177], ["COVID", "TEST", 216, 221], ["cardiac", "ANATOMY", 51, 58], ["injury", "OBSERVATION", 59, 65]]], ["6, 7 Difference in the cause of death in the two groups, if any, would help formulate better treatment strategies.", [["death", "DISEASE", 32, 37], ["death", "PROBLEM", 32, 37], ["treatment strategies", "TREATMENT", 93, 113]]], ["The age distribution of the propensity score matched cohort appears skewed, and further exploratory analysis assessing the overall survival in patients with different age groups would be interesting.Dear Editor,Overall, the study is very well conducted, and we congratulate the authors for achieving this mammoth task of collating and analyzing such a large database.", [["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["the propensity score", "PROBLEM", 24, 44], ["further exploratory analysis", "TEST", 80, 108], ["the study", "TEST", 220, 229], ["skewed", "OBSERVATION_MODIFIER", 68, 74], ["large", "OBSERVATION_MODIFIER", 352, 357]]]], "PMC7121487": [["To the Editor: As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections (causing coronavirus disease 2019 [Covid-19]) spread globally, uncertainty surrounds estimates of the true number of infected persons, which is crucial to determining the severity of infection and the incidence of mild or asymptomatic cases and their possible transmission.1 Modeling estimates suggest that in Wuhan, China, the city with the most Covid-19 cases, there are substantially more cases than were officially reported, because milder cases may not have been captured in hospital-based surveillance.2,3 Data on travelers returning from areas with cases of Covid-19 could be useful in estimating its incidence.4", [["acute respiratory syndrome coronavirus", "DISEASE", 25, 63], ["SARS-CoV-2) infections", "DISEASE", 67, 89], ["coronavirus disease", "DISEASE", 99, 118], ["infection", "DISEASE", 273, 282], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 18, 65], ["SARS-CoV-2", "ORGANISM", 67, 77], ["persons", "ORGANISM", 216, 223], ["travelers", "ORGANISM", 610, 619], ["persons", "SPECIES", 216, 223], ["severe acute respiratory syndrome coronavirus", "SPECIES", 18, 63], ["SARS-CoV-2", "SPECIES", 67, 77], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 18, 63], ["SARS", "PROBLEM", 67, 71], ["CoV", "TEST", 72, 75], ["infections", "PROBLEM", 79, 89], ["coronavirus disease", "PROBLEM", 99, 118], ["Covid", "TEST", 125, 130], ["spread globally", "PROBLEM", 136, 151], ["infection", "PROBLEM", 273, 282], ["mild or asymptomatic cases", "PROBLEM", 304, 330], ["travelers", "TREATMENT", 610, 619], ["Covid", "TEST", 655, 660], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["respiratory syndrome", "OBSERVATION", 31, 51], ["coronavirus disease", "OBSERVATION", 99, 118], ["true number", "OBSERVATION_MODIFIER", 192, 203], ["infected", "OBSERVATION", 207, 215], ["infection", "OBSERVATION", 273, 282], ["mild", "OBSERVATION_MODIFIER", 304, 308]]]], "8ac54a660da52d0df91cb9fb5469bfcb5746b8c4": [["BackgroundCorona virus disease 2019 , caused by the novel corona virus SARS-CoV-2, has the last few months taken hold of the world and spread as a global pandemic with presently more than 5.5 million cases 1 .", [["BackgroundCorona virus disease", "DISEASE", 0, 30], ["BackgroundCorona virus", "ORGANISM", 0, 22], ["corona virus SARS-CoV-2", "ORGANISM", 58, 81], ["BackgroundCorona virus disease 2019", "SPECIES", 0, 35], ["BackgroundCorona virus disease", "PROBLEM", 0, 30], ["the novel corona virus SARS", "PROBLEM", 48, 75], ["virus disease", "OBSERVATION", 17, 30]]], ["The lungs are the main target organ for COVID-19, and p atients who become critically ill generally suffer from respiratory distress leading to difficulties in ventilation and oxygenation.", [["lungs", "ANATOMY", 4, 9], ["organ", "ANATOMY", 30, 35], ["respiratory", "ANATOMY", 112, 123], ["critically ill", "DISEASE", 75, 89], ["respiratory distress", "DISEASE", 112, 132], ["lungs", "ORGAN", 4, 9], ["organ", "ORGAN", 30, 35], ["COVID", "TEST", 40, 45], ["critically ill", "PROBLEM", 75, 89], ["respiratory distress", "PROBLEM", 112, 132], ["difficulties in ventilation", "PROBLEM", 144, 171], ["oxygenation", "TEST", 176, 187], ["lungs", "ANATOMY", 4, 9], ["respiratory distress", "OBSERVATION", 112, 132]]], ["However, the respiratory symptoms in COVID-19 display atypical features, which have challenged the conventional mechanical ventilation strategies 2 .BackgroundA recent Dutch study of 184 COVID-19 positive patients treated at intensive care units (ICUs) showed a cumulative incidence of thrombotic events of 49%, mainly pulmonary embolism 2 .", [["respiratory", "ANATOMY", 13, 24], ["pulmonary", "ANATOMY", 319, 328], ["thrombotic", "DISEASE", 286, 296], ["pulmonary embolism", "DISEASE", 319, 337], ["patients", "ORGANISM", 205, 213], ["pulmonary", "ORGAN", 319, 328], ["patients", "SPECIES", 205, 213], ["the respiratory symptoms", "PROBLEM", 9, 33], ["COVID", "TEST", 37, 42], ["atypical features", "PROBLEM", 54, 71], ["the conventional mechanical ventilation strategies", "TREATMENT", 95, 145], ["Dutch study", "TEST", 168, 179], ["COVID", "TEST", 187, 192], ["thrombotic events", "PROBLEM", 286, 303], ["mainly pulmonary embolism", "PROBLEM", 312, 337], ["respiratory", "ANATOMY", 13, 24], ["atypical", "OBSERVATION_MODIFIER", 54, 62], ["mechanical ventilation", "OBSERVATION", 112, 134], ["thrombotic", "OBSERVATION", 286, 296], ["pulmonary", "ANATOMY", 319, 328], ["embolism", "OBSERVATION", 329, 337]]], ["Autopsy reports have confirmed and even exceeded this high rate of thrombosis 3, 4 , and have also shown a high prevalence of microthrombosis in the small veins of the lungs 5 .", [["small veins", "ANATOMY", 149, 160], ["lungs", "ANATOMY", 168, 173], ["thrombosis", "DISEASE", 67, 77], ["microthrombosis", "DISEASE", 126, 141], ["small veins", "MULTI-TISSUE_STRUCTURE", 149, 160], ["lungs", "ORGAN", 168, 173], ["Autopsy", "TEST", 0, 7], ["thrombosis", "PROBLEM", 67, 77], ["microthrombosis in the small veins of the lungs", "PROBLEM", 126, 173], ["thrombosis", "OBSERVATION", 67, 77], ["high", "OBSERVATION_MODIFIER", 107, 111], ["microthrombosis", "OBSERVATION", 126, 141], ["small veins", "ANATOMY", 149, 160], ["lungs", "ANATOMY", 168, 173]]], ["Thromboembolic complications may be a direct cause of death in COVID-19 3, 4 and in addition, the loss of perfusion caused by thrombi in the lungs will impair pulmonary gas exchange independently of the direct tissue damage caused by the viral pneumonia.", [["thrombi", "ANATOMY", 126, 133], ["lungs", "ANATOMY", 141, 146], ["pulmonary", "ANATOMY", 159, 168], ["tissue", "ANATOMY", 210, 216], ["Thromboembolic complications", "DISEASE", 0, 28], ["death", "DISEASE", 54, 59], ["thrombi", "DISEASE", 126, 133], ["pneumonia", "DISEASE", 244, 253], ["lungs", "ORGAN", 141, 146], ["pulmonary", "ORGAN", 159, 168], ["tissue", "TISSUE", 210, 216], ["Thromboembolic complications", "PROBLEM", 0, 28], ["death", "PROBLEM", 54, 59], ["COVID", "TEST", 63, 68], ["the loss of perfusion", "PROBLEM", 94, 115], ["thrombi in the lungs", "PROBLEM", 126, 146], ["pulmonary gas exchange", "PROBLEM", 159, 181], ["the direct tissue damage", "PROBLEM", 199, 223], ["the viral pneumonia", "PROBLEM", 234, 253], ["thrombi", "OBSERVATION", 126, 133], ["lungs", "ANATOMY", 141, 146], ["pulmonary", "ANATOMY", 159, 168], ["gas exchange", "OBSERVATION", 169, 181], ["viral", "OBSERVATION_MODIFIER", 238, 243], ["pneumonia", "OBSERVATION", 244, 253]]], ["This will contribute to the respiratory failure that is the main cause of critical disease in patients with COVID-19.BackgroundElevated levels of fibrin degradation products (e.g. d-dimer) have consistently been reported as a strong prognostic factor associated with poor outcome in patients with COVID-19 6, 7 .", [["respiratory", "ANATOMY", 28, 39], ["respiratory failure", "DISEASE", 28, 47], ["COVID-19", "CHEMICAL", 108, 116], ["patients", "ORGANISM", 94, 102], ["fibrin", "GENE_OR_GENE_PRODUCT", 146, 152], ["d-dimer", "GENE_OR_GENE_PRODUCT", 180, 187], ["patients", "ORGANISM", 283, 291], ["fibrin degradation products", "PROTEIN", 146, 173], ["dimer", "PROTEIN", 182, 187], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 283, 291], ["the respiratory failure", "PROBLEM", 24, 47], ["critical disease", "PROBLEM", 74, 90], ["COVID", "TEST", 108, 113], ["BackgroundElevated levels of fibrin degradation products", "PROBLEM", 117, 173], ["e.g. d-dimer", "TEST", 175, 187], ["COVID", "TEST", 297, 302], ["respiratory failure", "OBSERVATION", 28, 47], ["main", "OBSERVATION_MODIFIER", 60, 64], ["critical", "OBSERVATION_MODIFIER", 74, 82], ["disease", "OBSERVATION", 83, 90], ["Elevated", "OBSERVATION_MODIFIER", 127, 135], ["levels", "OBSERVATION_MODIFIER", 136, 142], ["fibrin degradation", "OBSERVATION", 146, 164]]], ["This suggests a general coagulation activation and secondary hyperfibrinolysis.", [["hyperfibrinolysis", "DISEASE", 61, 78], ["a general coagulation activation", "PROBLEM", 14, 46], ["secondary hyperfibrinolysis", "PROBLEM", 51, 78], ["general", "OBSERVATION_MODIFIER", 16, 23], ["coagulation", "OBSERVATION", 24, 35], ["secondary", "OBSERVATION_MODIFIER", 51, 60], ["hyperfibrinolysis", "OBSERVATION", 61, 78]]], ["However, the D-dimer increase is not evident in early stages of the disease 7 , limiting its usefulness as a prognostic marker.BackgroundMaximum clot firmness (MCF) may be calculated using Rotational Thromboelastometry (ROTEM) and is considered a good marker for hypercoagulopathy 8 .", [["clot", "ANATOMY", 145, 149], ["hypercoagulopathy", "DISEASE", 263, 280], ["D-dimer", "GENE_OR_GENE_PRODUCT", 13, 20], ["clot", "ORGANISM_SUBSTANCE", 145, 149], ["D-dimer", "PROTEIN", 13, 20], ["the D-dimer increase", "PROBLEM", 9, 29], ["the disease 7", "PROBLEM", 64, 77], ["a prognostic marker", "TEST", 107, 126], ["BackgroundMaximum clot firmness", "PROBLEM", 127, 158], ["Rotational Thromboelastometry (ROTEM", "TEST", 189, 225], ["hypercoagulopathy", "PROBLEM", 263, 280], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["not evident", "UNCERTAINTY", 33, 44], ["early stages", "OBSERVATION_MODIFIER", 48, 60], ["disease", "OBSERVATION", 68, 75], ["Maximum", "OBSERVATION_MODIFIER", 137, 144], ["clot", "OBSERVATION", 145, 149], ["firmness", "OBSERVATION_MODIFIER", 150, 158]]], ["Theoretically, ROTEM variables may be affected earlier during the disease course compared with d-dimer and may be of greater value as a predictor of disease severity.", [["ROTEM variables", "TEST", 15, 30], ["d-dimer", "TEST", 95, 102], ["disease severity", "PROBLEM", 149, 165], ["disease", "OBSERVATION", 149, 156]]], ["Studies assessing ROTEM in COVID-19 patients treated at ICUs have shown elevated MCF values 9, 10 .", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["Studies", "TEST", 0, 7], ["ROTEM", "TEST", 18, 23], ["COVID", "TEST", 27, 32], ["elevated MCF values", "PROBLEM", 72, 91], ["elevated", "OBSERVATION_MODIFIER", 72, 80], ["MCF", "OBSERVATION_MODIFIER", 81, 84]]], ["However, no ROTEM data at earlier stages of the disease have, to our knowledge, yet been reported.BackgroundThe aim of this study was to assess the presence of coagulopathy, measured by ROTEM, in COVID-19 patients at hospital admission.Study designThe study was designed as a prospective observational study and was approved by the Swedish Ethical Review Authority (D-nr 2020-01875).", [["coagulopathy", "DISEASE", 160, 172], ["D-nr 2020-01875", "CHEMICAL", 366, 381], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["ROTEM data", "TEST", 12, 22], ["the disease", "PROBLEM", 44, 55], ["this study", "TEST", 119, 129], ["coagulopathy", "PROBLEM", 160, 172], ["ROTEM", "TEST", 186, 191], ["The study", "TEST", 248, 257], ["a prospective observational study", "TEST", 274, 307], ["no", "UNCERTAINTY", 9, 11], ["disease", "OBSERVATION", 48, 55], ["coagulopathy", "OBSERVATION", 160, 172]]], ["Patients over 18 years of age, who tested positive for COVID-19 and were considered in need of hospital care were eligible for inclusion in the study.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 55, 60], ["hospital care", "TREATMENT", 95, 108], ["the study", "TEST", 140, 149]]], ["Recruitment of patients commenced May 8th, 2020, and is planned to continue for three months in total.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23]]], ["Here we report on subjects included up to May 31st, 2020.Study designAll patients were included at Capio St G\u00f6ran's Hospital (StG) in Stockholm, Sweden.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81]]], ["Patients presenting at StG Emergency Room with confirmed SARS-CoV-2 infections and in need of hospitalization are admitted either to regular wards with possibility of low-flow oxygen therapy (henceforth \"Regular ward\") or to wards with possibilities of specialized ventilation support; either non-invasive ventilation in intermediate wards (Biphasic Positive Airway Pressure (BiPAP) or High-Flow Oxygen Therapy (HFOT)) or to the Intensive Care Unit where, in addition to BiPAP and HFOT, mechanical ventilation support is provided (henceforth \"Specialized wards\").Study designCoagulation-related blood tests were drawn from all included patients (d-dimer, P-fibrinogen, APTT, INR, antithrombin, platelet count and ROTEM) as soon after admission to hospital as possible.", [["blood", "ANATOMY", 595, 600], ["platelet", "ANATOMY", 694, 702], ["SARS-CoV-2 infections", "DISEASE", 57, 78], ["oxygen", "CHEMICAL", 176, 182], ["oxygen", "CHEMICAL", 176, 182], ["Oxygen", "CHEMICAL", 396, 402], ["Patients", "ORGANISM", 0, 8], ["oxygen", "SIMPLE_CHEMICAL", 176, 182], ["BiPAP", "SIMPLE_CHEMICAL", 471, 476], ["blood", "ORGANISM_SUBSTANCE", 595, 600], ["patients", "ORGANISM", 636, 644], ["d-dimer", "SIMPLE_CHEMICAL", 646, 653], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 657, 667], ["APTT", "GENE_OR_GENE_PRODUCT", 669, 673], ["antithrombin", "GENE_OR_GENE_PRODUCT", 680, 692], ["platelet", "CELL", 694, 702], ["P", "PROTEIN", 655, 656], ["fibrinogen", "PROTEIN", 657, 667], ["APTT", "PROTEIN", 669, 673], ["INR", "PROTEIN", 675, 678], ["antithrombin", "PROTEIN", 680, 692], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 636, 644], ["SARS", "PROBLEM", 57, 61], ["CoV", "PROBLEM", 62, 65], ["2 infections", "PROBLEM", 66, 78], ["low-flow oxygen therapy", "TREATMENT", 167, 190], ["specialized ventilation support", "TREATMENT", 253, 284], ["non-invasive ventilation", "TREATMENT", 293, 317], ["Biphasic Positive Airway Pressure (BiPAP", "TREATMENT", 341, 381], ["High-Flow Oxygen Therapy", "TREATMENT", 386, 410], ["BiPAP", "TREATMENT", 471, 476], ["HFOT", "TREATMENT", 481, 485], ["mechanical ventilation support", "TREATMENT", 487, 517], ["Study designCoagulation", "TEST", 563, 586], ["blood tests", "TEST", 595, 606], ["P", "TEST", 655, 656], ["fibrinogen", "TEST", 657, 667], ["APTT", "TEST", 669, 673], ["INR", "TEST", 675, 678], ["antithrombin", "TEST", 680, 692], ["platelet count", "TEST", 694, 708], ["ROTEM", "TEST", 713, 718], ["SARS", "OBSERVATION", 57, 61], ["infections", "OBSERVATION", 68, 78], ["oxygen therapy", "OBSERVATION", 176, 190], ["Airway Pressure", "OBSERVATION", 359, 374]]], ["ROTEM test results were blinded for clinicians, but conventional coagulation tests were not.", [["ROTEM test", "TEST", 0, 10], ["conventional coagulation tests", "TEST", 52, 82]]], ["Relevant patient information was extracted from the medical journals.", [["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16]]], ["Aside from these blood tests, nothing was changed in the routine care of included patients.Study designAnticoagulant treatment (ACTr) after admission were divided into 5 groups: 0 (no treatment), 1 (low prophylactic dose LMWH = 75 IE/kg/24h), 2 (high prophylactic dose LMWH = 150 IE/kg/24h), 3 (treatment dose LMWH \u2265 200 IE/kg/24h) and 4 (pre-existing anticoagulant medication, e.g. new oral anticoagulants).Study designA ROTEM sigma (Tem Innovations GmbH, Germany) analyzing instrument was installed for the purpose of the study at StG laboratory.", [["blood", "ANATOMY", 17, 22], ["oral", "ANATOMY", 387, 391], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["patients", "ORGANISM", 82, 90], ["oral", "ORGANISM_SUBDIVISION", 387, 391], ["patients", "SPECIES", 82, 90], ["these blood tests", "TEST", 11, 28], ["Study designAnticoagulant treatment", "TREATMENT", 91, 126], ["low prophylactic dose LMWH", "TREATMENT", 199, 225], ["high prophylactic dose LMWH", "TREATMENT", 246, 273], ["LMWH", "TREATMENT", 310, 314], ["pre-existing anticoagulant medication", "TREATMENT", 339, 376], ["new oral anticoagulants", "TREATMENT", 383, 406], ["the study", "TEST", 520, 529]]], ["ROTEM sigma is a fully automated system with proven ROTEM technology, where pipetting and test preparation are not required.", [["ROTEM sigma", "GENE_OR_GENE_PRODUCT", 0, 11], ["ROTEM sigma", "PROTEIN", 0, 11], ["ROTEM technology", "TEST", 52, 68], ["pipetting and test preparation", "TEST", 76, 106]]], ["All blood samples were analyzed within four hours after they were drawn.Study designROTEM data from healthy individuals collected 2011-2012 for a previously published study were used as controls.", [["blood samples", "ANATOMY", 4, 17], ["blood samples", "ORGANISM_SUBSTANCE", 4, 17], ["All blood samples", "TEST", 0, 17], ["Study designROTEM data", "TEST", 72, 94], ["a previously published study", "TEST", 144, 172]]], ["The original publication contains further details 11 .ROTEM-tests.", [["ROTEM", "PROTEIN", 54, 59], ["ROTEM-tests", "TEST", 54, 65], ["publication", "OBSERVATION", 13, 24]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Two of four ROTEM-tests are presented here: i) extrinsically activated assays with tissue factor (EXTEM); ii) with tissue factor and the platelet inhibitor cytochalasin D (FIBTEM) 12 .(which was not certified by peer review)EXTEM tests the extrinsic coagulation pathway.", [["cytochalasin D", "CHEMICAL", 156, 170], ["cytochalasin D", "CHEMICAL", 156, 170], ["FIBTEM", "CHEMICAL", 172, 178], ["tissue", "TISSUE", 83, 89], ["tissue factor", "GENE_OR_GENE_PRODUCT", 115, 128], ["platelet", "CELL", 137, 145], ["cytochalasin D", "SIMPLE_CHEMICAL", 156, 170], ["ROTEM", "DNA", 12, 17], ["tissue factor", "PROTEIN", 83, 96], ["EXTEM", "PROTEIN", 98, 103], ["tissue factor", "PROTEIN", 115, 128], ["four ROTEM-tests", "TEST", 7, 23], ["tissue factor", "TREATMENT", 115, 128], ["the platelet inhibitor cytochalasin D (FIBTEM)", "TREATMENT", 133, 179], ["EXTEM tests", "TEST", 224, 235], ["the extrinsic coagulation pathway", "TEST", 236, 269]]], ["FIBTEM blocks the platelet contribution to clot formation, leaving only the impact of clotting proteins and the functional fibrinogen.", [["platelet", "ANATOMY", 18, 26], ["clot", "ANATOMY", 43, 47], ["platelet", "CELL", 18, 26], ["clot", "ORGANISM_SUBSTANCE", 43, 47], ["clotting proteins", "GENE_OR_GENE_PRODUCT", 86, 103], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 123, 133], ["clotting proteins", "PROTEIN", 86, 103], ["functional fibrinogen", "PROTEIN", 112, 133], ["clot formation", "PROBLEM", 43, 57], ["clotting proteins", "TREATMENT", 86, 103], ["the functional fibrinogen", "TEST", 108, 133], ["clot", "OBSERVATION", 43, 47], ["clotting", "OBSERVATION", 86, 94]]], ["Coagulation Time (CT) is the time (in seconds) from test start until an amplitude of 2 mm is reached, giving information about coagulation activation/initiation.", [["Coagulation Time", "TEST", 0, 16], ["CT", "TEST", 18, 20], ["coagulation activation", "TEST", 127, 149]]], ["Clot Formation Time (CFT) is the time (in seconds) between 2 mm amplitude and 20 mm amplitude, giving information about clot propagation.", [["Clot", "ANATOMY", 0, 4], ["clot", "ANATOMY", 120, 124], ["clot", "ORGANISM_SUBSTANCE", 120, 124], ["Clot Formation", "PROBLEM", 0, 14], ["clot propagation", "PROBLEM", 120, 136], ["clot", "OBSERVATION", 120, 124]]], ["Maximum Clot Firmness (MCF) is the maximum amplitude (in millimeters) reached during the test, giving information about clot stability.", [["clot", "ANATOMY", 120, 124], ["clot", "ORGANISM_SUBSTANCE", 120, 124], ["Maximum Clot Firmness", "PROBLEM", 0, 21], ["the test", "TEST", 85, 93], ["clot stability", "PROBLEM", 120, 134], ["Clot", "OBSERVATION", 8, 12], ["Firmness", "OBSERVATION_MODIFIER", 13, 21], ["MCF", "OBSERVATION_MODIFIER", 23, 26], ["maximum", "OBSERVATION_MODIFIER", 35, 42], ["amplitude", "OBSERVATION_MODIFIER", 43, 52], ["clot", "OBSERVATION", 120, 124]]], ["A short EXTEM-CFT and an increased EXTEM-MCF and/or FIBTEM-MCF suggest a hypercoagulable state.Statistical analysisAll continuous variables are presented as median and interquartile range (IQR).", [["EXTEM", "PROTEIN", 35, 40], ["A short EXTEM", "TEST", 0, 13], ["CFT", "TEST", 14, 17], ["an increased EXTEM", "PROBLEM", 22, 40], ["MCF", "PROBLEM", 41, 44], ["FIBTEM", "TEST", 52, 58], ["MCF", "PROBLEM", 59, 62], ["a hypercoagulable state", "PROBLEM", 71, 94], ["Statistical analysis", "TEST", 95, 115], ["short", "OBSERVATION_MODIFIER", 2, 7], ["increased", "OBSERVATION_MODIFIER", 25, 34], ["hypercoagulable state", "OBSERVATION", 73, 94]]], ["Kruskal-Wallis tests were used to test whether ROTEM data for COVID-19 patients differed depending on care level (Regular ward; Specialized ward), or from healthy controls.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["Kruskal-Wallis tests", "TEST", 0, 20], ["ROTEM data", "TEST", 47, 57], ["COVID", "TEST", 62, 67]]], ["If the tests were significant, pairwise two-sided Wilcoxon tests were performed.", [["the tests", "TEST", 3, 12], ["pairwise two-sided Wilcoxon tests", "TEST", 31, 64]]], ["Spearman's correlation coefficients were calculated to assess associations between variables.", [["Spearman's correlation coefficients", "TEST", 0, 35]]], ["P-values below 0.05 were considered statistically significant.", [["P-values", "TEST", 0, 8]]], ["No corrections for multiple comparisons were made.", [["multiple comparisons", "TEST", 19, 39]]], ["R version 4.0.0 was used to perform statistical analysis and visualizations.ResultsSixty COVID-19 positive patients and 89 healthy controls were included in the analysis.", [["patients", "ORGANISM", 107, 115], ["controls", "ORGANISM", 131, 139], ["patients", "SPECIES", 107, 115], ["R version", "TEST", 0, 9], ["statistical analysis", "TEST", 36, 56], ["visualizations", "TEST", 61, 75], ["ResultsSixty COVID", "TEST", 76, 94], ["the analysis", "TEST", 157, 169]]], ["Table 1 presents patient characteristics.", [["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24]]], ["Comorbidities were common within the COVID-19 patient group, where 42% of patients had a prior diagnosis of hypertension and 28% of diabetes.", [["hypertension", "DISEASE", 108, 120], ["diabetes", "DISEASE", 132, 140], ["patient", "ORGANISM", 46, 53], ["patients", "ORGANISM", 74, 82], ["patient", "SPECIES", 46, 53], ["patients", "SPECIES", 74, 82], ["Comorbidities", "PROBLEM", 0, 13], ["hypertension", "PROBLEM", 108, 120], ["diabetes", "PROBLEM", 132, 140], ["hypertension", "OBSERVATION", 108, 120], ["diabetes", "OBSERVATION", 132, 140]]], ["48 patients (80%) received prophylactic anticoagulant treatment (ACTr) after admission, whereof in 36 (60%) patients this treatment was administered before ROTEM was analyzed.", [["patients", "ORGANISM", 3, 11], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 108, 116], ["prophylactic anticoagulant treatment", "TREATMENT", 27, 63], ["this treatment", "TREATMENT", 117, 131], ["ROTEM", "TEST", 156, 161]]], ["Of patients with ACTr before ROTEM, 19 of these had low dose prophylaxis with Low Molecular Weight Heparin (LMWH), 7 had high dose prophylaxis with LMWH, 5 had treatment dose LMWH and 5 continued their regular anticoagulant medication.Results.", [["Heparin", "CHEMICAL", 99, 106], ["LMWH", "CHEMICAL", 108, 112], ["LMWH", "CHEMICAL", 148, 152], ["patients", "ORGANISM", 3, 11], ["Heparin", "SIMPLE_CHEMICAL", 99, 106], ["LMWH", "SIMPLE_CHEMICAL", 148, 152], ["patients", "SPECIES", 3, 11], ["ROTEM", "TEST", 29, 34], ["low dose prophylaxis", "TREATMENT", 52, 72], ["Low Molecular Weight Heparin (LMWH)", "TREATMENT", 78, 113], ["high dose prophylaxis", "TREATMENT", 121, 142], ["LMWH", "TREATMENT", 148, 152], ["treatment dose LMWH", "TREATMENT", 160, 179], ["their regular anticoagulant medication", "TREATMENT", 196, 234]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Figure S1 and S2.(which was not certified by peer review)For EXTEM-CT, the Kruskal-Wallis test showed a significant difference between the groups (H(2) = 97.1, p < 0.001).", [["S2", "PROTEIN", 14, 16], ["CT", "TEST", 67, 69], ["the Kruskal-Wallis test", "TEST", 71, 94], ["S2", "ANATOMY", 14, 16], ["significant", "OBSERVATION_MODIFIER", 104, 115], ["difference", "OBSERVATION", 116, 126]]], ["Post-hoc pairwise Wilcoxon tests showed that COVID-19 patients (both care levels) had significantly longer coagulation time compared with healthy controls (p<0.001) and that subjects treated at specialized wards had longer coagulation time compared with subjects treated at regular wards (p<0.001) ( Figure 1A ).(which was not certified by peer review)For EXTEM-MCF, the Kruskal-Wallis test showed a significant difference between the groups (H(2) = 39.3, p < 0.001).", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["Wilcoxon tests", "TEST", 18, 32], ["COVID", "TEST", 45, 50], ["the Kruskal-Wallis test", "TEST", 367, 390], ["significant", "OBSERVATION_MODIFIER", 400, 411], ["difference", "OBSERVATION", 412, 422]]], ["Post-hoc pairwise Wilcoxon tests showed that .", [["Wilcoxon tests", "TEST", 18, 32]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128710 doi: medRxiv preprint COVID-19 patients (both care levels) had significantly increased maximum clot amplitude compared to healthy controls (p<0.001) and that subjects treated at specialized wards had increased maximum clot amplitude compared with subjects treated at regular wards (p<0.01) ( Figure 1B ).(which was not certified by peer review)For EXTEM-CFT, the Kruskal-Wallis test showed a significant difference between the groups (H(2) = 64.8, p < 0.001).", [["clot", "ANATOMY", 416, 420], ["clot", "ANATOMY", 539, 543], ["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 352, 360], ["clot", "ORGANISM_SUBSTANCE", 416, 420], ["clot", "ORGANISM_SUBSTANCE", 539, 543], ["patients", "SPECIES", 352, 360], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint COVID", "TREATMENT", 326, 348], ["significantly increased maximum clot amplitude", "PROBLEM", 384, 430], ["increased maximum clot amplitude", "PROBLEM", 521, 553], ["EXTEM", "TEST", 669, 674], ["CFT", "TEST", 675, 678], ["the Kruskal-Wallis test", "TEST", 680, 703], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["increased", "OBSERVATION_MODIFIER", 398, 407], ["maximum", "OBSERVATION_MODIFIER", 408, 415], ["clot", "OBSERVATION", 416, 420], ["increased", "OBSERVATION_MODIFIER", 521, 530], ["maximum", "OBSERVATION_MODIFIER", 531, 538], ["clot", "OBSERVATION", 539, 543], ["significant", "OBSERVATION_MODIFIER", 713, 724], ["difference", "OBSERVATION", 725, 735]]], ["Post-hoc pairwise Wilcoxon tests showed that COVID-19 patients (both care levels) had significantly shorter clot formation time compared to healthy controls (p<0.001) ( Figure 1C ).(which was not certified by peer review)For FIBTEM-MCF, the Kruskal-Wallis test showed a significant difference between the groups (H(2) = 79.5, p < 0.001).", [["clot", "ANATOMY", 108, 112], ["patients", "ORGANISM", 54, 62], ["clot", "ORGANISM_SUBSTANCE", 108, 112], ["patients", "SPECIES", 54, 62], ["Wilcoxon tests", "TEST", 18, 32], ["COVID", "TEST", 45, 50], ["care levels", "TEST", 69, 80], ["significantly shorter clot formation", "PROBLEM", 86, 122], ["FIBTEM", "TEST", 225, 231], ["the Kruskal-Wallis test", "TEST", 237, 260], ["clot", "OBSERVATION", 108, 112], ["significant", "OBSERVATION_MODIFIER", 270, 281], ["difference", "OBSERVATION", 282, 292]]], ["Post-hoc pairwise Wilcoxon tests showed that COVID-19 patients (both care levels) had significantly increased maximum clot amplitude compared with healthy controls (p<0.001) and that subjects treated at specialized wards had increased maximum clot amplitude compared with subjects treated at regular wards (p=0.04) ( Figure 1D ).(which was not certified by peer review).", [["clot", "ANATOMY", 118, 122], ["clot", "ANATOMY", 243, 247], ["patients", "ORGANISM", 54, 62], ["clot", "ORGANISM_SUBSTANCE", 118, 122], ["clot", "ORGANISM_SUBSTANCE", 243, 247], ["patients", "SPECIES", 54, 62], ["Wilcoxon tests", "TEST", 18, 32], ["COVID", "TEST", 45, 50], ["care levels", "TEST", 69, 80], ["significantly increased maximum clot amplitude", "PROBLEM", 86, 132], ["increased maximum clot amplitude", "PROBLEM", 225, 257], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["maximum", "OBSERVATION_MODIFIER", 110, 117], ["clot", "OBSERVATION", 118, 122], ["increased", "OBSERVATION_MODIFIER", 225, 234], ["maximum", "OBSERVATION_MODIFIER", 235, 242], ["clot", "OBSERVATION", 243, 247]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. .Figure 1.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["ROTEM data.", [["ROTEM data", "TEST", 0, 10]]], ["Dashed horizontal lines are upper and lower reference values.p-values were calculated using a two-sided Wilcoxon signed rank test (ns = p > 0.05, * = p < 0.05, * * = p < 0.01, * * * = p < 0.001\", * * * * = p < 0.0001) .", [["horizontal lines", "ANATOMY", 7, 23], ["Dashed horizontal lines", "CELL", 0, 23], ["Dashed horizontal lines", "CELL_LINE", 0, 23], ["Dashed horizontal lines", "TREATMENT", 0, 23], ["ns", "TEST", 131, 133], ["horizontal lines", "OBSERVATION", 7, 23], ["upper", "ANATOMY_MODIFIER", 28, 33], ["lower", "ANATOMY_MODIFIER", 38, 43]]], ["In B) EXTEM Maximum Clot Firmness; C) EXTEM Clot Formation Time; and D) FIBTEM Maximum Clot Firmness.To assess the association between D-dimer and EXTEM-MCF, and P-Fibrinogen and FIBTEM-MCF at an early stage of the disease, Spearman's correlation coefficient was calculated for the subset of data where ROTEM data was available from the first day after hospital admission (N=34).", [["D-dimer", "GENE_OR_GENE_PRODUCT", 135, 142], ["Fibrinogen", "GENE_OR_GENE_PRODUCT", 164, 174], ["D-dimer", "PROTEIN", 135, 142], ["EXTEM", "PROTEIN", 147, 152], ["Fibrinogen", "PROTEIN", 164, 174], ["Maximum Clot Firmness", "PROBLEM", 12, 33], ["C) EXTEM Clot Formation", "PROBLEM", 35, 58], ["Maximum Clot Firmness", "PROBLEM", 79, 100], ["D-dimer", "TEST", 135, 142], ["EXTEM", "TEST", 147, 152], ["MCF", "TEST", 153, 156], ["P", "TEST", 162, 163], ["Fibrinogen", "TEST", 164, 174], ["FIBTEM", "TEST", 179, 185], ["MCF", "PROBLEM", 186, 189], ["the disease", "PROBLEM", 211, 222], ["Spearman's correlation", "TEST", 224, 246], ["ROTEM data", "TEST", 303, 313], ["Clot", "OBSERVATION", 20, 24], ["Firmness", "OBSERVATION_MODIFIER", 25, 33], ["Clot", "OBSERVATION", 44, 48], ["Maximum", "OBSERVATION_MODIFIER", 79, 86], ["Clot", "OBSERVATION", 87, 91], ["Firmness", "OBSERVATION_MODIFIER", 92, 100], ["disease", "OBSERVATION", 215, 222]]], ["There was no significant correlation between D-dimer and EXTEM-MCF (correlation = 0.02, p = 0.9).", [["D-dimer", "SIMPLE_CHEMICAL", 45, 52], ["D-dimer", "PROTEIN", 45, 52], ["D-dimer", "TEST", 45, 52], ["EXTEM", "TEST", 57, 62], ["correlation", "TEST", 68, 79], ["p", "TEST", 88, 89], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24]]], ["The correlation between P-Fibrinogen and FIBTEM-MCF was significant (correlation = 0.84, p < 0.001) (Figure 2 ).Figure 2 .", [["Fibrinogen", "GENE_OR_GENE_PRODUCT", 26, 36], ["P", "DNA", 24, 25], ["Fibrinogen", "PROTEIN", 26, 36], ["FIBTEM", "PROTEIN", 41, 47], ["P", "TEST", 24, 25], ["Fibrinogen", "TEST", 26, 36], ["FIBTEM", "TEST", 41, 47], ["correlation", "TEST", 69, 80]]], ["Scatter plots showing ROTEM data and coagulation markers for patients tested during the first day after admission.", [["patients", "ORGANISM", 61, 69], ["coagulation markers", "PROTEIN", 37, 56], ["patients", "SPECIES", 61, 69], ["Scatter plots", "TEST", 0, 13], ["ROTEM data", "TEST", 22, 32], ["coagulation markers", "TEST", 37, 56]]], ["In A) D-dimer plotted against EXTEM-MCF.", [["D-dimer", "SIMPLE_CHEMICAL", 6, 13], ["EXTEM", "PROTEIN", 30, 35], ["MCF", "PROBLEM", 36, 39]]], ["The red vertical line is the upper reference limit for EXTEM-MCF (72 mm); blue horizontal line is the upper reference limit for D-dimer (0.61 mg/L at age 61).", [["red vertical line", "ANATOMY", 4, 21], ["D-dimer", "CHEMICAL", 128, 135], ["D-dimer", "SIMPLE_CHEMICAL", 128, 135], ["red vertical line", "CELL_LINE", 4, 21], ["D-dimer", "PROTEIN", 128, 135], ["The red vertical line", "TREATMENT", 0, 21], ["EXTEM", "TEST", 55, 60], ["blue horizontal line", "TREATMENT", 74, 94], ["red", "OBSERVATION_MODIFIER", 4, 7], ["vertical line", "OBSERVATION", 8, 21], ["upper", "ANATOMY_MODIFIER", 29, 34], ["horizontal line", "OBSERVATION", 79, 94], ["upper", "ANATOMY_MODIFIER", 102, 107]]], ["Two D-dimer values higher than 3.5 are shown as triangles.", [["D-dimer", "GENE_OR_GENE_PRODUCT", 4, 11], ["Two D-dimer values", "TEST", 0, 18]]], ["In B) P-fibrinogen plotted against FIBTEM-MCF.", [["B) P-fibrinogen", "GENE_OR_GENE_PRODUCT", 3, 18], ["fibrinogen", "PROTEIN", 8, 18], ["FIBTEM", "PROTEIN", 35, 41], ["P", "TEST", 6, 7], ["fibrinogen", "TEST", 8, 18], ["MCF", "PROBLEM", 42, 45]]], ["The red vertical line is the upper reference limit for FIBTEM-MCF (25mm); blue horizontal line upper reference limit for P-Fibrinogen (4.2 g/L).Our results show that the median patient with COVID-19 related mild to severe acute respiratory distress treated at StG between 200508-200531, had laboratory results indicating coagulopathy, with significant differences in ROTEM variables compared .", [["red vertical line", "ANATOMY", 4, 21], ["respiratory", "ANATOMY", 228, 239], ["respiratory distress", "DISEASE", 228, 248], ["StG between 200508-200531", "CHEMICAL", 260, 285], ["coagulopathy", "DISEASE", 321, 333], ["patient", "ORGANISM", 177, 184], ["red vertical line", "CELL_LINE", 4, 21], ["P", "PROTEIN", 121, 122], ["Fibrinogen", "PROTEIN", 123, 133], ["patient", "SPECIES", 177, 184], ["The red vertical line", "TREATMENT", 0, 21], ["FIBTEM", "TEST", 55, 61], ["blue horizontal line", "TREATMENT", 74, 94], ["P", "TEST", 121, 122], ["Fibrinogen", "TEST", 123, 133], ["COVID", "TEST", 190, 195], ["mild to severe acute respiratory distress", "PROBLEM", 207, 248], ["coagulopathy", "PROBLEM", 321, 333], ["significant differences in ROTEM variables", "PROBLEM", 340, 382], ["red", "OBSERVATION_MODIFIER", 4, 7], ["vertical line", "OBSERVATION", 8, 21], ["upper", "ANATOMY_MODIFIER", 29, 34], ["upper", "ANATOMY_MODIFIER", 95, 100], ["mild", "OBSERVATION_MODIFIER", 207, 211], ["severe", "OBSERVATION_MODIFIER", 215, 221], ["acute", "OBSERVATION_MODIFIER", 222, 227], ["respiratory distress", "OBSERVATION", 228, 248], ["coagulopathy", "OBSERVATION", 321, 333], ["significant", "OBSERVATION_MODIFIER", 340, 351]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128710 doi: medRxiv preprint with healthy controls; longer EXTEM-CT, shorter EXTEM-CFT and increased EXTEM-MCF and FIBTEM-MCF.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["longer EXTEM", "TEST", 366, 378], ["CT", "TEST", 379, 381], ["shorter EXTEM", "TEST", 383, 396], ["CFT", "TEST", 397, 400], ["increased EXTEM", "PROBLEM", 405, 420], ["MCF", "PROBLEM", 436, 439], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["This suggests a patient with prolonged haemostatic initiation, shortened clot propagation and, notably, with a pronounced clot firmness indicating hypercoagulation.", [["clot", "ANATOMY", 73, 77], ["clot", "ANATOMY", 122, 126], ["hypercoagulation", "DISEASE", 147, 163], ["patient", "ORGANISM", 16, 23], ["clot", "ORGANISM_SUBSTANCE", 73, 77], ["clot", "ORGANISM_SUBSTANCE", 122, 126], ["patient", "SPECIES", 16, 23], ["prolonged haemostatic initiation", "TREATMENT", 29, 61], ["shortened clot propagation", "PROBLEM", 63, 89], ["a pronounced clot firmness", "PROBLEM", 109, 135], ["hypercoagulation", "PROBLEM", 147, 163], ["shortened", "OBSERVATION_MODIFIER", 63, 72], ["clot", "OBSERVATION", 73, 77], ["pronounced", "OBSERVATION_MODIFIER", 111, 121], ["clot", "OBSERVATION", 122, 126], ["hypercoagulation", "OBSERVATION", 147, 163]]], ["Fibrinolysis measured by clot lysis (Lysis index at time 30 minutes, LI30) was however not significantly increased.DiscussionIn this prospective observational study we assessed the level of coagulopathy in COVID-19 patients using ROTEM analysis.", [["clot", "ANATOMY", 25, 29], ["Fibrinolysis", "DISEASE", 0, 12], ["coagulopathy", "DISEASE", 190, 202], ["clot", "ORGANISM_SUBSTANCE", 25, 29], ["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 215, 223], ["Fibrinolysis", "TEST", 0, 12], ["clot lysis", "TEST", 25, 35], ["Lysis index", "TEST", 37, 48], ["this prospective observational study", "TEST", 128, 164], ["coagulopathy", "PROBLEM", 190, 202], ["COVID", "TEST", 206, 211], ["ROTEM analysis", "TEST", 230, 244], ["clot", "OBSERVATION", 25, 29], ["lysis", "OBSERVATION_MODIFIER", 30, 35], ["not", "UNCERTAINTY", 87, 90], ["significantly", "OBSERVATION_MODIFIER", 91, 104], ["increased", "OBSERVATION_MODIFIER", 105, 114], ["coagulopathy", "OBSERVATION", 190, 202]]], ["Previous studies have shown deranged values in critically ill patients 9, 10 .", [["critically ill", "DISEASE", 47, 61], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["Previous studies", "TEST", 0, 16], ["deranged values", "PROBLEM", 28, 43], ["deranged", "OBSERVATION_MODIFIER", 28, 36], ["values", "OBSERVATION_MODIFIER", 37, 43]]], ["To our knowledge, this is the first time data on less severely ill patients in the first 1-2 days after admission to hospital are published.", [["ill", "DISEASE", 63, 66], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75]]], ["In our sample, we observed significantly higher EXTEM-MCF and FIBTEM-MCF in patients treated at regular wards compared with healthy controls.", [["MCF", "DISEASE", 69, 72], ["FIBTEM-MCF", "CELL", 62, 72], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["FIBTEM", "TREATMENT", 62, 68], ["MCF", "PROBLEM", 69, 72]]], ["This indicates that coagulopathy is present early in the disease course, and suggests that ROTEM-analysis may potentially be a useful predictor of thromboembolic complications and mortality.DiscussionDuring the months since COVID-19 was classified as a pandemic, evidence has emerged indicating coagulopathy and thrombosis as central explanations to why some patients develop severe illness 2,3 .", [["coagulopathy", "DISEASE", 20, 32], ["thromboembolic", "DISEASE", 147, 161], ["coagulopathy", "DISEASE", 295, 307], ["thrombosis", "DISEASE", 312, 322], ["illness", "DISEASE", 383, 390], ["patients", "ORGANISM", 359, 367], ["patients", "SPECIES", 359, 367], ["coagulopathy", "PROBLEM", 20, 32], ["ROTEM-analysis", "TEST", 91, 105], ["thromboembolic complications", "PROBLEM", 147, 175], ["COVID", "TEST", 224, 229], ["coagulopathy", "PROBLEM", 295, 307], ["thrombosis", "PROBLEM", 312, 322], ["severe illness", "PROBLEM", 376, 390], ["coagulopathy", "OBSERVATION", 20, 32], ["thromboembolic", "OBSERVATION", 147, 161], ["coagulopathy", "OBSERVATION", 295, 307], ["thrombosis", "OBSERVATION", 312, 322], ["severe", "OBSERVATION_MODIFIER", 376, 382], ["illness", "OBSERVATION", 383, 390]]], ["The pattern of higher EXTEM-MCF and FIBTEM-MCF in more severely ill patients in our data strengthens this hypothesis that the atypical features of Acute Respiratory Distress Syndrome (ARDS) observed in COVID-19 patients may partly be caused by thromboembolism impairing lung perfusion.DiscussionIn line with these findings, increased D-dimer and P-fibrinogen have been reported to predict poor clinical outcome 6, 7 .", [["lung", "ANATOMY", 270, 274], ["MCF", "DISEASE", 43, 46], ["severely ill", "DISEASE", 55, 67], ["Respiratory Distress Syndrome", "DISEASE", 153, 182], ["ARDS", "DISEASE", 184, 188], ["thromboembolism", "DISEASE", 244, 259], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 211, 219], ["lung", "ORGAN", 270, 274], ["D-dimer", "GENE_OR_GENE_PRODUCT", 334, 341], ["P-fibrinogen", "GENE_OR_GENE_PRODUCT", 346, 358], ["D-dimer", "PROTEIN", 334, 341], ["P", "PROTEIN", 346, 347], ["fibrinogen", "PROTEIN", 348, 358], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 211, 219], ["Acute Respiratory Distress Syndrome", "PROBLEM", 147, 182], ["ARDS", "PROBLEM", 184, 188], ["thromboembolism impairing lung perfusion", "PROBLEM", 244, 284], ["increased D-dimer", "PROBLEM", 324, 341], ["P-fibrinogen", "TEST", 346, 358], ["higher", "OBSERVATION_MODIFIER", 15, 21], ["atypical", "OBSERVATION_MODIFIER", 126, 134], ["Acute", "OBSERVATION_MODIFIER", 147, 152], ["Respiratory Distress Syndrome", "OBSERVATION", 153, 182], ["may partly be caused", "UNCERTAINTY", 220, 240], ["thromboembolism", "OBSERVATION", 244, 259], ["lung", "ANATOMY", 270, 274], ["perfusion", "OBSERVATION", 275, 284]]], ["However, both these tests have caveats: the D-dimer blood test is nonspecific and may be increased in a variety of conditions including malignancy, inflammation and infection 13 ; fibrinogen is an acute phase reactant, and high levels of P-fibrinogen may reflect a patient with a high inflammatory profile, which itself may amplify the effects of other cardiovascular risk factors 14 .", [["blood", "ANATOMY", 52, 57], ["cardiovascular", "ANATOMY", 353, 367], ["malignancy", "DISEASE", 136, 146], ["inflammation", "DISEASE", 148, 160], ["infection", "DISEASE", 165, 174], ["D-dimer", "GENE_OR_GENE_PRODUCT", 44, 51], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["malignancy", "CANCER", 136, 146], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 180, 190], ["P-fibrinogen", "GENE_OR_GENE_PRODUCT", 238, 250], ["patient", "ORGANISM", 265, 272], ["fibrinogen", "PROTEIN", 180, 190], ["fibrinogen", "PROTEIN", 240, 250], ["patient", "SPECIES", 265, 272], ["these tests", "TEST", 14, 25], ["the D-dimer blood test", "TEST", 40, 62], ["malignancy", "PROBLEM", 136, 146], ["inflammation", "PROBLEM", 148, 160], ["infection", "PROBLEM", 165, 174], ["fibrinogen", "TEST", 180, 190], ["an acute phase reactant", "PROBLEM", 194, 217], ["P-fibrinogen", "TEST", 238, 250], ["a high inflammatory profile", "PROBLEM", 278, 305], ["other cardiovascular risk factors", "PROBLEM", 347, 380], ["nonspecific", "OBSERVATION_MODIFIER", 66, 77], ["may be", "UNCERTAINTY", 82, 88], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["malignancy", "OBSERVATION", 136, 146], ["inflammation", "OBSERVATION", 148, 160], ["infection", "OBSERVATION", 165, 174], ["acute", "OBSERVATION_MODIFIER", 197, 202], ["phase", "OBSERVATION_MODIFIER", 203, 208], ["inflammatory", "OBSERVATION", 285, 297]]], ["Conversely, ROTEM has been shown a better tool for monitoring coagulation profiles than conventional coagulation tests 15, 16 .DiscussionAs can be seen in Figure 2 , FIBTEM-MCF and P-fibrinogen are highly correlated in COVID-19 patients, whereas EXTEM-MCF supplies information that differs from D-dimer at an early disease stage.", [["P-fibrinogen", "GENE_OR_GENE_PRODUCT", 181, 193], ["patients", "ORGANISM", 228, 236], ["D-dimer", "GENE_OR_GENE_PRODUCT", 295, 302], ["ROTEM", "PROTEIN", 12, 17], ["fibrinogen", "PROTEIN", 183, 193], ["EXTEM", "PROTEIN", 246, 251], ["D-dimer", "PROTEIN", 295, 302], ["patients", "SPECIES", 228, 236], ["monitoring coagulation profiles", "TEST", 51, 82], ["conventional coagulation tests", "TEST", 88, 118], ["FIBTEM", "TEST", 166, 172], ["fibrinogen", "TEST", 183, 193], ["COVID", "TEST", 219, 224], ["an early disease stage", "PROBLEM", 306, 328], ["early", "OBSERVATION_MODIFIER", 309, 314], ["disease", "OBSERVATION", 315, 322]]], ["If individuals at risk of developing COVID-19 related thromboses are identified at an early stage, enhanced prophylaxis with LMWH may decrease mortality in this group of patients 6 17 .", [["COVID", "DISEASE", 37, 42], ["thromboses", "DISEASE", 54, 64], ["LMWH", "CHEMICAL", 125, 129], ["COVID-19", "CHEMICAL", 37, 45], ["thromboses", "PATHOLOGICAL_FORMATION", 54, 64], ["LMWH", "SIMPLE_CHEMICAL", 125, 129], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["developing COVID-19 related thromboses", "PROBLEM", 26, 64], ["enhanced prophylaxis", "TREATMENT", 99, 119], ["LMWH", "TREATMENT", 125, 129], ["19 related", "OBSERVATION_MODIFIER", 43, 53], ["thromboses", "OBSERVATION", 54, 64]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 12, 2020. . could be applied for this purpose.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Whether the ROTEM data will have better predictive characteristics compared with conventional coagulation tests does, however, remain to be shown.(which was not certified by peer review)Sepsis is known to exert a complex effect on the coagulation system, generally affecting all aspects of clot formation, kinetic activity and clot development 18 .", [["clot", "ANATOMY", 290, 294], ["clot", "ANATOMY", 327, 331], ["Sepsis", "DISEASE", 186, 192], ["clot", "ORGANISM_SUBSTANCE", 290, 294], ["clot", "ORGANISM_SUBSTANCE", 327, 331], ["the ROTEM data", "TEST", 8, 22], ["conventional coagulation tests", "TEST", 81, 111], ["Sepsis", "PROBLEM", 186, 192], ["a complex effect on the coagulation system", "PROBLEM", 211, 253], ["clot formation", "PROBLEM", 290, 304], ["clot development", "PROBLEM", 327, 343], ["complex", "OBSERVATION_MODIFIER", 213, 220], ["effect", "OBSERVATION", 221, 227], ["clot", "OBSERVATION", 290, 294], ["kinetic activity", "OBSERVATION", 306, 322], ["clot", "OBSERVATION", 327, 331]]], ["Already in the early stages of sepsis the coagulation system and the platelets are strongly activated 19 .", [["platelets", "ANATOMY", 69, 78], ["sepsis", "DISEASE", 31, 37], ["platelets", "CELL", 69, 78], ["platelets", "CELL_TYPE", 69, 78], ["sepsis the coagulation system", "PROBLEM", 31, 60], ["the platelets", "TEST", 65, 78], ["early stages", "OBSERVATION_MODIFIER", 15, 27], ["sepsis", "OBSERVATION", 31, 37]]], ["However, it has been recently shown that the coagulopathy related to the COVID-19 pathogenesis differs from the disseminated intravascular coagulation (DIC) associated with sepsis, with relatively normal levels of INR, APTT and platelets despite markedly elevated d-dimer levels 20 21 .", [["intravascular", "ANATOMY", 125, 138], ["platelets", "ANATOMY", 228, 237], ["coagulopathy", "DISEASE", 45, 57], ["intravascular coagulation", "DISEASE", 125, 150], ["DIC", "DISEASE", 152, 155], ["sepsis", "DISEASE", 173, 179], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 125, 138], ["INR", "GENE_OR_GENE_PRODUCT", 214, 217], ["APTT", "GENE_OR_GENE_PRODUCT", 219, 223], ["platelets", "CELL", 228, 237], ["INR", "PROTEIN", 214, 217], ["APTT", "PROTEIN", 219, 223], ["platelets", "CELL_TYPE", 228, 237], ["the coagulopathy", "PROBLEM", 41, 57], ["the COVID", "TEST", 69, 78], ["the disseminated intravascular coagulation", "PROBLEM", 108, 150], ["sepsis", "PROBLEM", 173, 179], ["INR", "TEST", 214, 217], ["APTT", "TEST", 219, 223], ["platelets", "TEST", 228, 237], ["markedly elevated d-dimer levels", "PROBLEM", 246, 278], ["coagulopathy", "OBSERVATION", 45, 57], ["disseminated", "OBSERVATION_MODIFIER", 112, 124], ["intravascular coagulation", "OBSERVATION", 125, 150], ["sepsis", "OBSERVATION", 173, 179]]], ["Nevertheless, whether this hypercoagulability is due to the characteristics of the invading microorganism, the individual viral load, or the massive host inflammatory response remains unknown.", [["hypercoagulability", "DISEASE", 27, 45], ["this hypercoagulability", "PROBLEM", 22, 45], ["the invading microorganism", "PROBLEM", 79, 105], ["the individual viral load", "TEST", 107, 132], ["the massive host inflammatory response", "PROBLEM", 137, 175], ["viral load", "OBSERVATION", 122, 132], ["massive", "OBSERVATION_MODIFIER", 141, 148], ["host", "OBSERVATION_MODIFIER", 149, 153], ["inflammatory response", "OBSERVATION", 154, 175]]], ["The coagulopathy related to COVID-19 ARDS may in some way be specific for the SARS-CoV-2 species, representing new features that need to be further explored.LimitationsOur study has limitations.", [["coagulopathy", "DISEASE", 4, 16], ["ARDS", "DISEASE", 37, 41], ["SARS", "DISEASE", 78, 82], ["SARS-CoV-2 species", "ORGANISM", 78, 96], ["The coagulopathy", "PROBLEM", 0, 16], ["COVID", "TEST", 28, 33], ["ARDS", "PROBLEM", 37, 41], ["the SARS", "PROBLEM", 74, 82], ["CoV-2 species", "PROBLEM", 83, 96], ["Our study", "TEST", 168, 177], ["coagulopathy", "OBSERVATION", 4, 16], ["ARDS", "OBSERVATION", 37, 41], ["SARS", "OBSERVATION", 78, 82], ["new", "OBSERVATION_MODIFIER", 111, 114]]], ["First, 60% of patients had received usually low dose anticoagulant treatment before ROTEM analysis, which may have to some degree counteracted hypercoagulation.", [["hypercoagulation", "DISEASE", 143, 159], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["usually low dose anticoagulant treatment", "TREATMENT", 36, 76], ["ROTEM analysis", "TEST", 84, 98], ["some degree counteracted hypercoagulation", "PROBLEM", 118, 159], ["hypercoagulation", "OBSERVATION", 143, 159]]], ["However, despite this limitation, ROTEM results were highly significantly increased in covid-19 patients compared with normal controls.", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["ROTEM results", "TEST", 34, 47], ["covid", "TEST", 87, 92], ["significantly", "OBSERVATION_MODIFIER", 60, 73], ["increased", "OBSERVATION_MODIFIER", 74, 83]]], ["Second, not all patients admitted for COVID-19 at St G\u00f6ran's Hospital during this period were tested using ROTEM, and not all patients that were included were tested during the first day after admission.", [["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 126, 134], ["COVID", "TEST", 38, 43], ["ROTEM", "TEST", 107, 112]]], ["The main reasons for this were: (i) Due to clinical duties the physicians responsible for the study were not always able to scan the wards for new patients on a daily basis (ii) and more importantly, limitation of the testing equipment, with possibility to run a maximum of 6 tests every 4 hours.", [["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["the study", "TEST", 90, 99], ["the testing equipment", "TEST", 214, 235], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Still, we believe that the included patients are a representative cross-section of the COVID-19 patients treated at St G\u00f6ran's Hospital during the study period.ConclusionIn hospitalized COVID-19 positive patients, elevated values of EXTEM-MCF and FIBTEM-MCF were seen at admission to hospital.", [["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 204, 212], ["COVID", "TEST", 186, 191], ["elevated values of EXTEM", "PROBLEM", 214, 238], ["MCF", "PROBLEM", 239, 242], ["FIBTEM", "TEST", 247, 253], ["MCF", "PROBLEM", 254, 257]]], ["This pattern was more pronounced in patients with significantly increased disease severity who needed transfer to specialized wards and is likely reflecting a hypercoagulable state.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["significantly increased disease severity", "PROBLEM", 50, 90], ["a hypercoagulable state", "PROBLEM", 157, 180], ["more pronounced", "OBSERVATION_MODIFIER", 17, 32], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["disease", "OBSERVATION", 74, 81], ["likely reflecting", "UNCERTAINTY", 139, 156], ["hypercoagulable state", "OBSERVATION", 159, 180]]], ["Whether early ROTEM-analysis at admission to hospital may predict outcome .", [["early ROTEM", "TEST", 8, 19]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)ConclusionThe copyright holder for this preprint this version posted June 12, 2020. . https://doi.org/10.1101/2020.06.11.20128710 doi: medRxiv preprint (mortality, thrombosis) in COVID-19 positive patients will be analyzed at a later stage of this research project.", [["CC", "CHEMICAL", 0, 2], ["thrombosis", "DISEASE", 366, 376], ["patients", "ORGANISM", 399, 407], ["patients", "SPECIES", 399, 407], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 212, 232], ["medRxiv", "TREATMENT", 337, 344], ["thrombosis", "PROBLEM", 366, 376], ["COVID", "TEST", 381, 386], ["med", "ANATOMY", 105, 108], ["thrombosis", "OBSERVATION", 366, 376]]]], "6a1c50c9c3ed91ec7b9f5a3e0fd68783e6b2f9a8": [["Accepted Articlebelieve that the conclusions made within this article should be taken with caution as the outcomes of patients co-infected with HIV and SARS-CoV-2 are not definitive and evidence regarding this matter is constantly evolving.Accepted ArticleAdadi et al. base their conclusions upon a narrow review of only three small case reports of HIV/SARS-CoV-2 co-infection, in which there are only 10 patients considered in total [2] [3] [4] .", [["HIV", "DISEASE", 144, 147], ["SARS", "DISEASE", 152, 156], ["HIV/SARS-CoV-2 co-infection", "DISEASE", 349, 376], ["patients", "ORGANISM", 118, 126], ["HIV", "ORGANISM", 144, 147], ["SARS-CoV-2", "ORGANISM", 152, 162], ["HIV", "ORGANISM", 349, 352], ["SARS-CoV-2", "ORGANISM", 353, 363], ["patients", "ORGANISM", 405, 413], ["patients", "SPECIES", 118, 126], ["HIV", "SPECIES", 144, 147], ["CoV-2", "SPECIES", 358, 363], ["patients", "SPECIES", 405, 413], ["HIV", "SPECIES", 144, 147], ["SARS-CoV", "SPECIES", 152, 160], ["HIV/SARS-CoV-2", "SPECIES", 349, 363], ["HIV", "PROBLEM", 144, 147], ["SARS", "PROBLEM", 152, 156], ["CoV", "TEST", 157, 160], ["this matter", "PROBLEM", 205, 216], ["HIV", "PROBLEM", 349, 352], ["SARS", "PROBLEM", 353, 357], ["CoV", "PROBLEM", 358, 361], ["2 co-infection", "PROBLEM", 362, 376]]], ["This analysis fails to include the more extensive case series and retrospective reviews which demonstrate uncertain outcomes of HIV/SARS-CoV-2 patients, despite these being published well in advance of their review.", [["SARS", "DISEASE", 132, 136], ["HIV", "ORGANISM", 128, 131], ["SARS-CoV-2", "ORGANISM", 132, 142], ["patients", "ORGANISM", 143, 151], ["HIV", "SPECIES", 128, 131], ["patients", "SPECIES", 143, 151], ["HIV", "SPECIES", 128, 131], ["This analysis", "TEST", 0, 13], ["retrospective reviews", "TEST", 66, 87], ["HIV/SARS", "PROBLEM", 128, 136]]], ["These extensive studies have called for further research in order to better understand the risks of COVID-19 among people living with HIV and the impact of antiretroviral therapy on outcomes for these patients [5] .", [["HIV", "DISEASE", 134, 137], ["people", "ORGANISM", 115, 121], ["patients", "ORGANISM", 201, 209], ["people", "SPECIES", 115, 121], ["HIV", "SPECIES", 134, 137], ["patients", "SPECIES", 201, 209], ["HIV", "SPECIES", 134, 137], ["These extensive studies", "TEST", 0, 23], ["COVID", "TEST", 100, 105], ["HIV", "PROBLEM", 134, 137], ["antiretroviral therapy", "TREATMENT", 156, 178]]], ["These studies include, but are not limited to: Vizcarra [2] .", [["These studies", "TEST", 0, 13]]], ["This report received criticism due to its lack of patient details regarding sexual history, drug use, blood transfusion, antiretroviral treatment [17] .", [["blood", "ANATOMY", 102, 107], ["patient", "ORGANISM", 50, 57], ["blood", "ORGANISM_SUBSTANCE", 102, 107], ["patient", "SPECIES", 50, 57], ["blood transfusion", "TREATMENT", 102, 119], ["antiretroviral treatment", "TREATMENT", 121, 145]]], ["This report also mentioned that the patient was given an \"antigen/antibody combination test for HIV detection\" without mentioning why the test was given as the patient was hospitalized for COVID-19, or whether or not the test was repeated.", [["patient", "ORGANISM", 36, 43], ["patient", "ORGANISM", 160, 167], ["patient", "SPECIES", 36, 43], ["patient", "SPECIES", 160, 167], ["HIV", "SPECIES", 96, 99], ["an \"antigen/antibody combination test", "TREATMENT", 54, 91], ["HIV detection", "TEST", 96, 109], ["the test", "TEST", 134, 142], ["COVID", "TEST", 189, 194], ["the test", "TEST", 217, 225]]], ["There was no confirmation of HIV diagnosis in this patient, and the antiretroviral treatment regimen mentioned is outside of the standard guidelines for HIV patients [17] .", [["HIV", "ORGANISM", 29, 32], ["patient", "ORGANISM", 51, 58], ["HIV", "ORGANISM", 153, 156], ["patients", "ORGANISM", 157, 165], ["patient", "SPECIES", 51, 58], ["HIV", "SPECIES", 153, 156], ["patients", "SPECIES", 157, 165], ["HIV", "SPECIES", 29, 32], ["HIV", "SPECIES", 153, 156], ["HIV diagnosis", "PROBLEM", 29, 42], ["the antiretroviral treatment regimen", "TREATMENT", 64, 100], ["no confirmation of", "UNCERTAINTY", 10, 28], ["HIV", "OBSERVATION", 29, 32]]], ["This patient did not receive antiretroviral therapy priorAccepted Articleco-infected with HIV and SARS-CoV-2 in Spain [4] .", [["Articleco-infected", "DISEASE", 66, 84], ["SARS", "DISEASE", 98, 102], ["patient", "ORGANISM", 5, 12], ["HIV", "ORGANISM", 90, 93], ["SARS-CoV-2", "ORGANISM", 98, 108], ["patient", "SPECIES", 5, 12], ["HIV", "SPECIES", 90, 93], ["HIV", "SPECIES", 90, 93], ["SARS-CoV", "SPECIES", 98, 106], ["antiretroviral therapy", "TREATMENT", 29, 51], ["Articleco", "TREATMENT", 66, 75], ["HIV", "PROBLEM", 90, 93], ["SARS", "PROBLEM", 98, 102]]], ["This study received criticism as it failed to report on the proportion of COVID-19 patients tested for HIV and the study sample included patients only from a single hospital in Spain [19] .", [["patients", "ORGANISM", 83, 91], ["HIV", "ORGANISM", 103, 106], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 83, 91], ["HIV", "SPECIES", 103, 106], ["patients", "SPECIES", 137, 145], ["HIV", "SPECIES", 103, 106], ["This study", "TEST", 0, 10], ["COVID", "TEST", 74, 79], ["HIV", "PROBLEM", 103, 106], ["the study sample", "TEST", 111, 127]]], ["Thus, the statements regarding the incidence of COVID-19 in HIV patients provided in this study can be easily misinterpreted and are thus falsely reassuring due to sampling constraints.", [["COVID-19", "CHEMICAL", 48, 56], ["HIV", "ORGANISM", 60, 63], ["patients", "ORGANISM", 64, 72], ["HIV", "SPECIES", 60, 63], ["patients", "SPECIES", 64, 72], ["HIV", "SPECIES", 60, 63], ["COVID", "TEST", 48, 53], ["this study", "TEST", 85, 95], ["sampling constraints", "PROBLEM", 164, 184]]], ["In their reply, Blanco et al. acknowledged the need for further studies before defining the epidemiological and clinical features of HIV/SARS-CoV-2 co-infected patients [21] .", [["HIV/SARS-CoV-2 co-infected", "DISEASE", 133, 159], ["HIV/SARS-CoV-2", "ORGANISM", 133, 147], ["patients", "ORGANISM", 160, 168], ["HIV", "SPECIES", 133, 136], ["CoV-", "SPECIES", 142, 146], ["patients", "SPECIES", 160, 168], ["HIV/SARS-CoV", "SPECIES", 133, 145], ["further studies", "TEST", 56, 71], ["HIV", "PROBLEM", 133, 136], ["SARS", "PROBLEM", 137, 141], ["CoV", "TEST", 142, 145]]], ["This is paired with the reality that universal HIV testing across the world is still non-existent and challenges with COVID-19 testing remain unsolved in many countries, making it difficult to calculate the incidence of these two viral infections occurring simultaneously in patients and generalize conclusions based on the outcomes of this narrow patient population [19] .", [["infections", "DISEASE", 236, 246], ["patients", "ORGANISM", 275, 283], ["patient", "ORGANISM", 348, 355], ["patients", "SPECIES", 275, 283], ["patient", "SPECIES", 348, 355], ["HIV", "SPECIES", 47, 50], ["universal HIV testing", "TEST", 37, 58], ["COVID", "TEST", 118, 123], ["these two viral infections", "PROBLEM", 220, 246], ["viral", "OBSERVATION_MODIFIER", 230, 235], ["infections", "OBSERVATION", 236, 246]]]], "45941ed8f762dc103b0d583b7e4e349be1ef6341": [["VerdictThe evidence included in this review is mostly derived from clinical studies involving adult participants and examining short-term use of commercial formulations of S.nigra berry for up to 16 days.", [["S.nigra berry", "CHEMICAL", 172, 185], ["S.nigra berry", "ORGANISM", 172, 185], ["participants", "SPECIES", 100, 112], ["clinical studies", "TEST", 67, 83], ["commercial formulations of S.nigra berry", "TREATMENT", 145, 185]]], ["Findings from included studies suggest that mono-herbal preparations of S.nigra berry (in extract or lozenge formulation) may reduce influenza-type symptoms, including fever, headache, nasal congestion and nasal mucous discharge in adults, when taken within the first 48 hours of symptom onset.", [["extract", "ANATOMY", 90, 97], ["nasal", "ANATOMY", 185, 190], ["nasal mucous", "ANATOMY", 206, 218], ["S.nigra berry", "CHEMICAL", 72, 85], ["influenza-type symptoms", "DISEASE", 133, 156], ["fever", "DISEASE", 168, 173], ["headache", "DISEASE", 175, 183], ["nasal congestion", "DISEASE", 185, 201], ["S.nigra berry", "ORGANISM", 72, 85], ["lozenge", "ORGANISM_SUBDIVISION", 101, 108], ["nasal", "ORGANISM_SUBDIVISION", 185, 190], ["nasal mucous", "MULTI-TISSUE_STRUCTURE", 206, 218], ["studies", "TEST", 23, 30], ["mono-herbal preparations", "TREATMENT", 44, 68], ["S.nigra berry", "TREATMENT", 72, 85], ["lozenge formulation", "TREATMENT", 101, 120], ["influenza", "PROBLEM", 133, 142], ["type symptoms", "PROBLEM", 143, 156], ["fever", "PROBLEM", 168, 173], ["headache", "PROBLEM", 175, 183], ["nasal congestion", "PROBLEM", 185, 201], ["nasal mucous discharge", "PROBLEM", 206, 228], ["symptom onset", "PROBLEM", 280, 293], ["nasal", "ANATOMY", 185, 190], ["congestion", "OBSERVATION", 191, 201], ["nasal mucous", "ANATOMY", 206, 218]]], ["Within 2-4 days of S.nigra treatment, most adult participants experienced significant symptom reduction, by an average of 50%.", [["S.nigra", "CHEMICAL", 19, 26], ["S.nigra", "SIMPLE_CHEMICAL", 19, 26], ["participants", "ORGANISM", 49, 61], ["participants", "SPECIES", 49, 61], ["S.nigra treatment", "TREATMENT", 19, 36], ["significant symptom reduction", "PROBLEM", 74, 103]]], ["Evidence regarding the effectiveness of S.nigra berry on the symptom of cough, and need for / use of medicines (including antibiotics) to treat acute respiratory infections, is currently unclear and inconsistent.", [["respiratory", "ANATOMY", 150, 161], ["S.nigra berry", "CHEMICAL", 40, 53], ["cough", "DISEASE", 72, 77], ["acute respiratory infections", "DISEASE", 144, 172], ["S.nigra berry", "ORGANISM", 40, 53], ["cough", "PROBLEM", 72, 77], ["medicines", "TREATMENT", 101, 110], ["antibiotics", "TREATMENT", 122, 133], ["acute respiratory infections", "PROBLEM", 144, 172], ["acute", "OBSERVATION_MODIFIER", 144, 149], ["respiratory", "ANATOMY", 150, 161], ["infections", "OBSERVATION", 162, 172]]], ["Adverse events were rare with no serious events reported.", [["Adverse events", "PROBLEM", 0, 14], ["serious events", "PROBLEM", 33, 47]]], ["Adverse events, reported in two studies, were more common in comparators than in treatments.", [["Adverse events", "PROBLEM", 0, 14], ["two studies", "TEST", 28, 39]]], ["There is currently no reliable or sufficient scientific evidence to support the use of S.nigra in pregnant or lactating women.BackgroundThe S. nigra plant belongs to the Adoxaceae family, which is indigenous to Europe, Asia and North Africa (1) .", [["S.nigra", "CHEMICAL", 87, 94], ["S.nigra", "SIMPLE_CHEMICAL", 87, 94], ["women", "ORGANISM", 120, 125], ["S. nigra plant", "ORGANISM", 140, 154], ["Adoxaceae", "GENE_OR_GENE_PRODUCT", 170, 179], ["women", "SPECIES", 120, 125], ["S. nigra", "SPECIES", 140, 148], ["S. nigra", "SPECIES", 140, 148], ["S.nigra", "TREATMENT", 87, 94], ["no", "UNCERTAINTY", 19, 21]]], ["Historically, the flower and berry of the Elder plant have been used in herbal preparations for the treatment of common cold and flu (1) .", [["flower", "ANATOMY", 18, 24], ["berry", "ANATOMY", 29, 34], ["flower", "ORGANISM_SUBDIVISION", 18, 24], ["berry", "ORGANISM_SUBDIVISION", 29, 34], ["herbal preparations", "TREATMENT", 72, 91], ["the treatment", "TREATMENT", 96, 109], ["common cold and flu", "PROBLEM", 113, 132]]], ["Preclinical studies have shown elderberry extracts to have antimicrobial and antiviral effects, including activity against influenza viruses (2) .", [["extracts", "ANATOMY", 42, 50], ["influenza viruses", "DISEASE", 123, 140], ["elderberry extracts", "ORGANISM_SUBSTANCE", 31, 50], ["influenza viruses", "ORGANISM", 123, 140], ["Preclinical studies", "TEST", 0, 19], ["elderberry extracts", "PROBLEM", 31, 50], ["antimicrobial", "TREATMENT", 59, 72], ["antiviral effects", "TREATMENT", 77, 94], ["influenza viruses", "PROBLEM", 123, 140]]], ["These antiviral effects have been attributed to the inhibition of viral replication by S.nigra.", [["S.nigra", "SIMPLE_CHEMICAL", 87, 94], ["viral replication", "TREATMENT", 66, 83], ["antiviral", "OBSERVATION", 6, 15], ["viral replication", "OBSERVATION", 66, 83]]], ["Additionally, elderberry extracts have been shown to increase cytokines that activate immunomodulation (3).BackgroundS.nigra berries contain multiple constituents, including flavonoids, triterpenes, acyl spermidines, \u03b1linolenic acid, linoleic acid (1), mucilage and hydroxycinnamic acid derivatives (4) .", [["extracts", "ANATOMY", 25, 33], ["acyl spermidines", "CHEMICAL", 199, 215], ["\u03b1linolenic acid, linoleic acid (1), mucilage and hydroxycinnamic acid", "CHEMICAL", 217, 286], ["flavonoids", "CHEMICAL", 174, 184], ["triterpenes", "CHEMICAL", 186, 197], ["acyl spermidines", "CHEMICAL", 199, 215], ["\u03b1linolenic acid", "CHEMICAL", 217, 232], ["linoleic acid", "CHEMICAL", 234, 247], ["hydroxycinnamic acid", "CHEMICAL", 266, 286], ["elderberry extracts", "ORGANISM_SUBSTANCE", 14, 33], ["flavonoids", "SIMPLE_CHEMICAL", 174, 184], ["triterpenes", "SIMPLE_CHEMICAL", 186, 197], ["acyl spermidines", "SIMPLE_CHEMICAL", 199, 215], ["\u03b1linolenic acid", "SIMPLE_CHEMICAL", 217, 232], ["linoleic acid (1)", "SIMPLE_CHEMICAL", 234, 251], ["mucilage", "SIMPLE_CHEMICAL", 253, 261], ["hydroxycinnamic acid derivatives", "SIMPLE_CHEMICAL", 266, 298], ["cytokines", "PROTEIN", 62, 71], ["multiple constituents", "PROBLEM", 141, 162], ["flavonoids", "TREATMENT", 174, 184], ["triterpenes", "TREATMENT", 186, 197], ["acyl spermidines", "TREATMENT", 199, 215], ["\u03b1linolenic acid", "TREATMENT", 217, 232], ["linoleic acid", "TREATMENT", 234, 247], ["mucilage and hydroxycinnamic acid derivatives", "TREATMENT", 253, 298], ["multiple", "OBSERVATION_MODIFIER", 141, 149], ["constituents", "OBSERVATION_MODIFIER", 150, 162]]], ["The rich anthocycanin flavonoid content is associated with antioxidant activity (5) .", [["anthocycanin flavonoid", "CHEMICAL", 9, 31], ["anthocycanin flavonoid", "CHEMICAL", 9, 31], ["anthocycanin flavonoid", "SIMPLE_CHEMICAL", 9, 31], ["flavonoid content", "OBSERVATION", 22, 39]]], ["The unripe berries also contain toxic constituents, but these are lost during drying and heating processes; as such, these toxic constituents are not typically present in commercially available preparations (3).Search StrategyResearch question Does S.nigra improve outcomes in humans with acute respiratory viral infections?Inclusion criteriaOriginal prospective intervention studies involving adult participants with acute respiratory viral infections written in English that evaluated the effect of S.nigra (as a mono-or combination therapy) in any form, dose and route of administration.", [["berries", "ANATOMY", 11, 18], ["respiratory viral infections", "DISEASE", 295, 323], ["respiratory viral infections", "DISEASE", 424, 452], ["S.nigra", "CHEMICAL", 501, 508], ["berries", "ORGANISM_SUBDIVISION", 11, 18], ["humans", "ORGANISM", 277, 283], ["S.nigra", "SIMPLE_CHEMICAL", 501, 508], ["humans", "SPECIES", 277, 283], ["participants", "SPECIES", 400, 412], ["humans", "SPECIES", 277, 283], ["toxic constituents", "PROBLEM", 32, 50], ["acute respiratory viral infections", "PROBLEM", 289, 323], ["Inclusion criteriaOriginal prospective intervention", "TREATMENT", 324, 375], ["acute respiratory viral infections", "PROBLEM", 418, 452], ["S.nigra", "TREATMENT", 501, 508], ["a mono", "TREATMENT", 513, 519], ["combination therapy", "TREATMENT", 523, 542], ["unripe berries", "OBSERVATION", 4, 18], ["toxic", "OBSERVATION_MODIFIER", 32, 37], ["constituents", "OBSERVATION_MODIFIER", 38, 50], ["acute", "OBSERVATION_MODIFIER", 289, 294], ["respiratory", "ANATOMY", 295, 306], ["viral infections", "OBSERVATION", 307, 323], ["acute", "OBSERVATION_MODIFIER", 418, 423], ["respiratory", "ANATOMY", 424, 435], ["viral infections", "OBSERVATION", 436, 452]]], ["All comparators or controls were included.Exclusion criteriaStudies involving children, or participants with bacterial, fungal or non-infectious respiratory disease and not meeting the inclusion criteria above were excluded from this review.DatabasesRelevant studies were identified by searching MEDLINE (Ovid), EMBASE (Ovid), AMED (Ovid) and CINAHL (EBSCO) for articles published from inception to May 2020.Screening and Data extractionOne author (KO) scanned the title and abstract of each record retrieved.", [["respiratory", "ANATOMY", 145, 156], ["non-infectious respiratory disease", "DISEASE", 130, 164], ["children", "ORGANISM", 78, 86], ["children", "SPECIES", 78, 86], ["participants", "SPECIES", 91, 103], ["bacterial, fungal or non-infectious respiratory disease", "PROBLEM", 109, 164], ["Screening", "TEST", 408, 417], ["Data extraction", "TEST", 422, 437], ["fungal", "OBSERVATION_MODIFIER", 120, 126], ["non-infectious", "OBSERVATION_MODIFIER", 130, 144], ["respiratory disease", "OBSERVATION", 145, 164]]], ["For articles that met the inclusion criteria, two authors (KO and JMC) extracted the relevant population and intervention characteristics into an extraction template, with any disagreements resolved by discussion with AS.Screening and Data extractionWhere duplicate papers and papers reporting aspects of the primary study, the authors (JMC and AS) checked the data aligned before removing the secondary paper and the original publication (typically the older paper) was included.Screening and Data extractionThe risk of bias of each study was evaluated by KO and JMC, using the Cochrane Collaboration Risk of Bias tool (6) , and checked by AS.", [["an extraction template", "TREATMENT", 143, 165], ["Screening", "TEST", 221, 230], ["Data extraction", "TEST", 235, 250], ["the primary study", "TEST", 305, 322], ["Screening", "TEST", 480, 489], ["Data extraction", "TEST", 494, 509], ["each study", "TEST", 529, 539], ["Bias tool", "TEST", 610, 619]]], ["Any disagreements were resolved by consensus.", [["Any disagreements", "PROBLEM", 0, 17]]], ["The Cochrane Risk of Bias tool is comprised of seven domains including; random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias.", [["participants", "SPECIES", 136, 148], ["Bias tool", "TEST", 21, 30], ["random sequence generation", "TREATMENT", 72, 98], ["outcome assessors", "TEST", 176, 193]]], ["'Yes' indicated a low risk of bias, and 'No' a high risk of bias and 'Unclear' indicating unclear or unknown risk of bias. (see Table 3 ).Data analysisData were synthesised in narrative form.", [["Data analysisData", "TEST", 138, 155]]], ["Due to the heterogeneity of the data, a meta-analysis was not conducted.ResultsThe database search identified 40 studies.", [["a meta-analysis", "TEST", 38, 53], ["The database search", "TEST", 79, 98], ["40 studies", "TEST", 110, 120]]], ["After the removal of duplicates (n=10), 30 studies were screened by title and abstract.", [["the removal of duplicates", "TREATMENT", 6, 31], ["30 studies", "TEST", 40, 50]]], ["This resulted in the exclusion of 15 studies.", [["the exclusion of 15 studies", "TEST", 17, 44]]], ["The remaining 15 studies were screened as full text.", [["The remaining 15 studies", "TEST", 0, 24]]], ["Ten studies were excluded as they reported the wrong study design (n=4), were a systematic review (n=4) or duplicated already included studies (n=2).", [["Ten studies", "TEST", 0, 11], ["the wrong study", "TEST", 43, 58], ["a systematic review", "TEST", 78, 97], ["studies", "TEST", 135, 142]]], ["Five studies were included for full review.", [["Five studies", "TEST", 0, 12]]], ["The included studies involved a total of 936 participants (minimum 27, maximum 473, mean 187).", [["participants", "SPECIES", 45, 57], ["The included studies", "TEST", 0, 20]]], ["The study population were primarily adults aged between 18 and 70 years, with two studies also including children aged from 5 years (7) or 12 years (8).", [["children", "ORGANISM", 105, 113], ["children", "SPECIES", 105, 113]]], ["The most common conditions studied were influenza (7-9) and influenza-like symptoms (10), followed by common cold (11) .ResultsAll included studies used a proprietary herbal medicine product as the intervention.", [["influenza", "DISEASE", 40, 49], ["influenza-like symptoms", "DISEASE", 60, 83], ["influenza", "PROBLEM", 40, 49], ["influenza", "PROBLEM", 60, 69], ["symptoms", "PROBLEM", 75, 83], ["a proprietary herbal medicine", "TREATMENT", 153, 182], ["the intervention", "TREATMENT", 194, 210]]], ["Four studies used mono-herbal preparations of S.nigra berry extract (7, (9) (10) (11) .", [["S.nigra berry extract", "CHEMICAL", 46, 67], ["S.nigra berry", "SPECIES", 46, 59], ["Four studies", "TEST", 0, 12], ["mono-herbal preparations", "TREATMENT", 18, 42], ["S.nigra berry extract", "TREATMENT", 46, 67]]], ["One study used a poly-herbal preparation, which contained S.nigra berry plus Echinacea purpurea root (8) .", [["root", "ANATOMY", 96, 100], ["poly-herbal", "CHEMICAL", 17, 28], ["S.nigra berry plus Echinacea purpurea", "CHEMICAL", 58, 95], ["S.nigra berry", "ORGANISM", 58, 71], ["Echinacea", "ORGANISM", 77, 86], ["S.nigra berry", "SPECIES", 58, 71], ["Echinacea purpurea", "SPECIES", 77, 95], ["Echinacea purpurea", "SPECIES", 77, 95], ["One study", "TEST", 0, 9], ["a poly-herbal preparation", "TREATMENT", 15, 40]]], ["The preparations were administered orally in the form of a syrup (7, 10), capsules (11), granules (8) or lozenges (9) .", [["granules", "ANATOMY", 89, 97], ["syrup", "ORGANISM_SUBDIVISION", 59, 64], ["granules", "ORGANISM_SUBSTANCE", 89, 97], ["The preparations", "TREATMENT", 0, 16], ["a syrup", "TREATMENT", 57, 64]]], ["Doses ranged from 15mls four times per day (syrup), 3 capsules per day, 175mg lozenge four times per day or 5ml of the poly-herbal formula in 150ml of hot water using an initial dosage of 5 times per day for days 1-3 followed by a maintenance dose of twice per day (days 4-10).Critical appraisalThe risk of bias assessment for the first domain (randomisation process) resulted in all 5 studies being rated as having a low risk of bias (7) (8) (9) (10) (11) .", [["syrup", "ORGANISM_SUBDIVISION", 44, 49], ["the poly-herbal formula", "TREATMENT", 115, 138], ["bias assessment", "TEST", 307, 322], ["the first domain (randomisation process", "PROBLEM", 327, 366]]], ["For domain 2 (treatment assignment), two studies were considered to have some concerns (8, 9) , and three studies were rated as having low risk of bias (7, 10, 11) .", [["two studies", "TEST", 37, 48], ["three studies", "TEST", 100, 113]]], ["For domain 4 (measure of outcomes), all five studies were rated as having low risk of bias (7) (8) (9) (10) (11) .", [["domain 4", "PROTEIN", 4, 12], ["all five studies", "TEST", 36, 52]]], ["Overall, two studies were identified as having some concerns (8, 9) and three studies were judged as having J o u r n a l P r e -p r o o f low risk of bias (7, 10, 11) .", [["two studies", "TEST", 9, 20], ["three studies", "TEST", 72, 85], ["low risk of bias", "PROBLEM", 139, 155], ["bias", "OBSERVATION", 151, 155]]], ["These judgements should be taken into consideration when interpreting the findings of this review.Summary of FindingsTreatment outcomes reported included overall reduction in symptoms; duration of illness/rate of recovery, and the use of rescue medication including analgesics, nasal spray, cold tablets, antibiotics.Summary of FindingsFour studies (7, (9) (10) (11) ) measured reduction of symptoms; fever reduction (7, (9) (10) (11) and one study (9) also reported reduction of headache, muscle ache, nasal congestion and mucus discharge and cough All studies reported (7-11) a reduction in overall symptom severity among participants receiving S.nigra berry (whether in mono-or poly-herbal formulation) when compared with controls.", [["nasal", "ANATOMY", 278, 283], ["muscle", "ANATOMY", 490, 496], ["nasal", "ANATOMY", 503, 508], ["mucus", "ANATOMY", 524, 529], ["illness", "DISEASE", 197, 204], ["fever", "DISEASE", 401, 406], ["headache", "DISEASE", 480, 488], ["muscle ache", "DISEASE", 490, 501], ["nasal congestion", "DISEASE", 503, 519], ["cough", "DISEASE", 544, 549], ["S.nigra berry", "CHEMICAL", 647, 660], ["nasal", "ORGANISM_SUBDIVISION", 278, 283], ["muscle", "ORGAN", 490, 496], ["ache", "ORGANISM_SUBDIVISION", 497, 501], ["nasal", "ORGANISM_SUBDIVISION", 503, 508], ["mucus", "ORGANISM_SUBSTANCE", 524, 529], ["S.nigra berry", "ORGANISM", 647, 660], ["participants", "SPECIES", 624, 636], ["overall reduction in symptoms", "PROBLEM", 154, 183], ["illness", "PROBLEM", 197, 204], ["rescue medication", "TREATMENT", 238, 255], ["analgesics", "TREATMENT", 266, 276], ["nasal spray", "TREATMENT", 278, 289], ["cold tablets", "TREATMENT", 291, 303], ["antibiotics", "TREATMENT", 305, 316], ["Four studies", "TEST", 336, 348], ["measured reduction of symptoms", "PROBLEM", 369, 399], ["fever reduction", "PROBLEM", 401, 416], ["one study", "TEST", 439, 448], ["headache", "PROBLEM", 480, 488], ["muscle ache", "PROBLEM", 490, 501], ["nasal congestion", "PROBLEM", 503, 519], ["mucus discharge", "PROBLEM", 524, 539], ["cough", "PROBLEM", 544, 549], ["All studies", "TEST", 550, 561], ["a reduction in overall symptom severity", "PROBLEM", 578, 617], ["poly-herbal formulation", "TREATMENT", 681, 704], ["reduction", "OBSERVATION_MODIFIER", 162, 171], ["reduction", "OBSERVATION_MODIFIER", 467, 476], ["headache", "OBSERVATION", 480, 488], ["muscle ache", "ANATOMY", 490, 501], ["nasal", "ANATOMY", 503, 508], ["congestion", "OBSERVATION", 509, 519]]], ["One study reported that participants receiving treatment reported significant improvement in symptom severity following 48 hours whereas the control group reported increased severity in the same time-period (8).Summary of FindingsDuration of illness and rate of recovery was reported in four studies (7, 8, 10, 11) .", [["FindingsDuration of illness", "DISEASE", 222, 249], ["participants", "SPECIES", 24, 36], ["One study", "TEST", 0, 9], ["treatment", "TREATMENT", 47, 56], ["symptom severity", "PROBLEM", 93, 109], ["increased severity", "PROBLEM", 164, 182], ["illness", "PROBLEM", 242, 249]]], ["Three studies demonstrated that the duration of illness was almost 50% shorter for those receiving S.nigra berry compared with the control group (7, 10, 11) .", [["illness", "DISEASE", 48, 55], ["S.nigra berry", "CHEMICAL", 99, 112], ["Three studies", "TEST", 0, 13], ["illness", "PROBLEM", 48, 55]]], ["In one study, the rate of recovery was similar between a S.nigra polyherbal preparation and an active control (Oseltamivir) (8) .Summary of FindingsIn the two studies (10, 11) reporting the use of rescue medication including analgesics, antibiotics, nasal sprays, or cold tablets to manage participant symptoms, the need for such medication was found to be inconsistent.", [["nasal", "ANATOMY", 250, 255], ["S.nigra", "CHEMICAL", 57, 64], ["Oseltamivir", "CHEMICAL", 111, 122], ["Oseltamivir", "CHEMICAL", 111, 122], ["one study", "TEST", 3, 12], ["a S.nigra polyherbal preparation", "TREATMENT", 55, 87], ["an active control (Oseltamivir)", "TREATMENT", 92, 123], ["rescue medication", "TREATMENT", 197, 214], ["analgesics", "TREATMENT", 225, 235], ["antibiotics", "TREATMENT", 237, 248], ["nasal sprays", "TREATMENT", 250, 262], ["cold tablets", "TREATMENT", 267, 279], ["participant symptoms", "PROBLEM", 290, 310], ["such medication", "TREATMENT", 325, 340], ["active", "OBSERVATION_MODIFIER", 95, 101]]], ["In one study, participants assigned to S.nigra berry treatment reported using rescue medication to manage influenza-like symptoms less frequently than control participants (10) .", [["S.nigra berry", "CHEMICAL", 39, 52], ["influenza-like symptoms", "DISEASE", 106, 129], ["participants", "ORGANISM", 14, 26], ["S.nigra", "ORGANISM", 39, 46], ["berry", "ORGANISM_SUBDIVISION", 47, 52], ["participants", "SPECIES", 14, 26], ["participants", "SPECIES", 159, 171], ["berry treatment", "TREATMENT", 47, 62], ["rescue medication", "TREATMENT", 78, 95], ["influenza", "PROBLEM", 106, 115], ["symptoms", "PROBLEM", 121, 129]]], ["By contrast, a second study found no difference between groups in the reported use of rescue medication or prescribed antibiotics among participants with the common cold (11).Adverse eventsAdverse events were rare with one study (11) reporting two adverse events (fatigue and cold-like symptoms) attributed to S.nigra berry compared to three (itchy throat, fatigue and kidney pain) attributed to placebo.", [["throat", "ANATOMY", 349, 355], ["kidney", "ANATOMY", 369, 375], ["fatigue", "DISEASE", 264, 271], ["itchy throat", "DISEASE", 343, 355], ["fatigue", "DISEASE", 357, 364], ["kidney pain", "DISEASE", 369, 380], ["throat", "ORGANISM_SUBDIVISION", 349, 355], ["kidney", "ORGAN", 369, 375], ["participants", "SPECIES", 136, 148], ["a second study", "TEST", 13, 27], ["rescue medication", "TREATMENT", 86, 103], ["prescribed antibiotics", "TREATMENT", 107, 129], ["Adverse eventsAdverse events", "PROBLEM", 175, 203], ["one study", "TEST", 219, 228], ["two adverse events", "PROBLEM", 244, 262], ["fatigue", "PROBLEM", 264, 271], ["cold-like symptoms", "PROBLEM", 276, 294], ["itchy throat", "PROBLEM", 343, 355], ["fatigue", "PROBLEM", 357, 364], ["kidney pain", "PROBLEM", 369, 380], ["placebo", "TREATMENT", 396, 403], ["kidney", "ANATOMY", 369, 375]]], ["A second study (8)Clinical significanceOverall, the evidence obtained from the five studies included in this review involving 936 people suggests that mono-herbal preparations of S.nigra berry when taken close to the onset of symptoms and for up to two weeks, may assist in relieving the symptoms of the common cold and influenza.Clinical significanceS.nigra berry may be effective in reducing the duration and severity of fever, headache, nasal J o u r n a l P r e -p r o o f congestion and nasal mucous discharge when associated with an acute viral respiratory infection.Clinical significanceSome evidence suggests that S.nigra berry may relieve cough or help prevent the worsening of cough when attributed to such viral infections however this finding is inconsistent across studies.", [["berry", "ANATOMY", 187, 192], ["berry", "ANATOMY", 359, 364], ["nasal", "ANATOMY", 440, 445], ["nasal mucous", "ANATOMY", 492, 504], ["respiratory", "ANATOMY", 551, 562], ["berry", "ANATOMY", 630, 635], ["S.nigra berry", "CHEMICAL", 179, 192], ["influenza", "DISEASE", 320, 329], ["fever", "DISEASE", 423, 428], ["headache", "DISEASE", 430, 438], ["viral respiratory infection", "DISEASE", 545, 572], ["S.nigra berry", "CHEMICAL", 622, 635], ["cough", "DISEASE", 648, 653], ["cough", "DISEASE", 687, 692], ["viral infections", "DISEASE", 717, 733], ["people", "ORGANISM", 130, 136], ["S.nigra berry", "ORGANISM", 179, 192], ["nasal mucous", "MULTI-TISSUE_STRUCTURE", 492, 504], ["S.nigra berry", "ORGANISM", 622, 635], ["people", "SPECIES", 130, 136], ["A second study", "TEST", 0, 14], ["the five studies", "TEST", 75, 91], ["symptoms", "PROBLEM", 226, 234], ["the symptoms", "PROBLEM", 284, 296], ["the common cold", "PROBLEM", 300, 315], ["influenza", "PROBLEM", 320, 329], ["fever", "PROBLEM", 423, 428], ["headache", "PROBLEM", 430, 438], ["congestion", "PROBLEM", 477, 487], ["nasal mucous discharge", "PROBLEM", 492, 514], ["an acute viral respiratory infection", "PROBLEM", 536, 572], ["cough", "PROBLEM", 648, 653], ["cough", "PROBLEM", 687, 692], ["such viral infections", "PROBLEM", 712, 733], ["common cold", "ANATOMY", 304, 315], ["influenza", "OBSERVATION", 320, 329], ["fever", "OBSERVATION", 423, 428], ["nasal", "ANATOMY", 440, 445], ["congestion", "OBSERVATION", 477, 487], ["nasal mucous", "ANATOMY", 492, 504], ["acute", "OBSERVATION_MODIFIER", 539, 544], ["viral", "OBSERVATION_MODIFIER", 545, 550], ["respiratory", "ANATOMY", 551, 562], ["infection", "OBSERVATION", 563, 572], ["worsening", "OBSERVATION_MODIFIER", 674, 683], ["cough", "OBSERVATION", 687, 692], ["infections", "OBSERVATION", 723, 733]]], ["As the formulation, dose and duration of S.nigra berry treatment varied between studies, general recommendations regarding these clinically important factors cannot be made.", [["S.nigra berry", "CHEMICAL", 41, 54], ["S.nigra berry treatment", "TREATMENT", 41, 64]]], ["Accordingly, TGAapproved monographs and pharmacopoeias (12)", [["pharmacopoeias", "TEST", 40, 54]]]], "a523960d520289a280ab44de22d719c4b0fb6a20": [["IntroductionThe outbreak of coronavirus in 2019-2020 is caused by Severe Acute Respiratory Syndrome Corona Virus (SARS-COV-2) [1] [2] [3] [4] .", [["coronavirus", "DISEASE", 28, 39], ["Acute Respiratory Syndrome Corona Virus", "DISEASE", 73, 112], ["SARS", "DISEASE", 114, 118], ["coronavirus", "ORGANISM", 28, 39], ["1] [2] [3] [4]", "SIMPLE_CHEMICAL", 127, 141], ["Severe Acute Respiratory Syndrome Corona Virus (SARS-COV-2", "SPECIES", 66, 124], ["coronavirus", "PROBLEM", 28, 39], ["Severe Acute Respiratory Syndrome", "PROBLEM", 66, 99], ["Corona Virus (SARS", "TEST", 100, 118], ["COV", "TEST", 119, 122], ["Severe", "OBSERVATION_MODIFIER", 66, 72], ["Acute", "OBSERVATION_MODIFIER", 73, 78], ["Respiratory Syndrome", "OBSERVATION", 79, 99]]], ["It is a positive-sense single-stranded RNA virus that caused a total of 75,465 reported cases up to February 2020 in China [5] [6] .", [["a positive-sense single-stranded RNA virus", "PROBLEM", 6, 48]]], ["Increased risk of world wide spread comprises serious life-threatening issues against human safety.", [["human", "ORGANISM", 86, 91], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["wide", "OBSERVATION_MODIFIER", 24, 28], ["spread", "OBSERVATION_MODIFIER", 29, 35]]], ["Fever, cough, and shortness of breath are the main symptoms of the disease that may leads eventually to pneumonia with a mortality rate of 1-3% [7] [8] [9] [10] [11] .IntroductionCurrently, there are no approved drugs for coronavirus infectious.", [["Fever", "DISEASE", 0, 5], ["cough", "DISEASE", 7, 12], ["shortness of breath", "DISEASE", 18, 37], ["pneumonia", "DISEASE", 104, 113], ["coronavirus infectious", "DISEASE", 222, 244], ["[7] [8] [9] [10", "SIMPLE_CHEMICAL", 144, 159], ["coronavirus", "ORGANISM", 222, 233], ["Fever", "PROBLEM", 0, 5], ["cough", "PROBLEM", 7, 12], ["shortness of breath", "PROBLEM", 18, 37], ["the main symptoms", "PROBLEM", 42, 59], ["the disease", "PROBLEM", 63, 74], ["pneumonia", "PROBLEM", 104, 113], ["a mortality rate", "TEST", 119, 135], ["coronavirus infectious", "PROBLEM", 222, 244], ["cough", "OBSERVATION", 7, 12], ["disease", "OBSERVATION", 67, 74], ["pneumonia", "OBSERVATION", 104, 113], ["no", "UNCERTAINTY", 200, 202], ["infectious", "OBSERVATION", 234, 244]]], ["Even though antiviral drugs such as inhibitors against protease, integrase and or polymerase enzymes designed and are in advance studies [12] [13] .", [["protease", "PROTEIN", 55, 63], ["integrase and or polymerase enzymes", "PROTEIN", 65, 100], ["antiviral drugs", "TREATMENT", 12, 27], ["inhibitors", "TREATMENT", 36, 46], ["protease", "TREATMENT", 55, 63], ["integrase", "TREATMENT", 65, 74], ["polymerase enzymes", "TEST", 82, 100]]], ["Among these inhibitors, anti-protease inhibitors seem to act effectively in blocking virus replication and provide a promising treatment for SARS and MERS diseases.IntroductionGiven the protease vital role in the virus life cycle and its maturation via functional protein production from their precursor, it seems to be a good target for drug design in viral infections as COVID-19 infection as well.IntroductionBased on data available in the PUBMED database (https://www.ncbi.nlm.nih.gov/pubmed/) COVID-19 protease, EC 3.4.2 is a protein with 305 residues contrast to SARS protease with 306 amino acid residues.", [["SARS", "DISEASE", 141, 145], ["MERS diseases", "DISEASE", 150, 163], ["viral infections", "DISEASE", 353, 369], ["infection", "DISEASE", 382, 391], ["SARS", "DISEASE", 569, 573], ["amino acid", "CHEMICAL", 592, 602], ["amino acid", "CHEMICAL", 592, 602], ["COVID-19", "ORGANISM", 373, 381], ["COVID-19 protease", "GENE_OR_GENE_PRODUCT", 498, 515], ["EC 3.4.2", "GENE_OR_GENE_PRODUCT", 517, 525], ["amino acid", "AMINO_ACID", 592, 602], ["protease", "PROTEIN", 186, 194], ["COVID-19 protease", "PROTEIN", 498, 515], ["EC 3.4.2", "PROTEIN", 517, 525], ["SARS protease", "PROTEIN", 569, 582], ["COVID-19", "SPECIES", 373, 381], ["these inhibitors", "TREATMENT", 6, 22], ["anti-protease inhibitors", "TREATMENT", 24, 48], ["blocking virus replication", "TREATMENT", 76, 102], ["a promising treatment", "TREATMENT", 115, 136], ["SARS", "PROBLEM", 141, 145], ["MERS diseases", "PROBLEM", 150, 163], ["the protease vital role", "TREATMENT", 182, 205], ["the virus life cycle", "TREATMENT", 209, 229], ["functional protein production", "PROBLEM", 253, 282], ["viral infections", "PROBLEM", 353, 369], ["COVID-19 infection", "PROBLEM", 373, 391], ["COVID", "TEST", 498, 503], ["EC", "TEST", 517, 519], ["a protein", "TEST", 529, 538], ["SARS protease", "TREATMENT", 569, 582], ["amino acid residues", "TREATMENT", 592, 611], ["viral infections", "OBSERVATION", 353, 369], ["infection", "OBSERVATION", 382, 391]]], ["Sequence alignment using EMBOSS Stretcher server (www.ebi.ac.uk) reviled that corona protease compared to SARS protease contains one amino acid deletion at position 144 (Cys) as well as about 10 mutations along it sequence stretch as depicted in scheme 1.", [["SARS", "DISEASE", 106, 110], ["amino acid", "CHEMICAL", 133, 143], ["amino acid", "CHEMICAL", 133, 143], ["Cys", "CHEMICAL", 170, 173], ["amino acid", "AMINO_ACID", 133, 143], ["Cys", "AMINO_ACID", 170, 173], ["EMBOSS Stretcher server", "DNA", 25, 48], ["corona protease", "PROTEIN", 78, 93], ["SARS protease", "PROTEIN", 106, 119], ["position 144", "PROTEIN", 156, 168], ["corona protease", "PROBLEM", 78, 93], ["SARS protease", "TREATMENT", 106, 119], ["one amino acid deletion", "TREATMENT", 129, 152]]], ["These changes in COVID-19 protease sequence may lead to the different global architecture of protein and especially in its binding or catalytic site, in such a way the localization of binding sites in COVID-19 shifted to neighbors' residues contrast to that's of SARS protease.IntroductionBinding site survey for these two proteases using Computed Atlas of Surface Topography of proteins (http://sts.bioe.uic.edu/castp/) server confirmed these changes in enzyme binding site.", [["SARS", "DISEASE", 263, 267], ["COVID-19", "CHEMICAL", 201, 209], ["COVID-19", "GENE_OR_GENE_PRODUCT", 17, 25], ["COVID-19", "GENE_OR_GENE_PRODUCT", 201, 209], ["SARS protease", "GENE_OR_GENE_PRODUCT", 263, 276], ["COVID-19 protease sequence", "DNA", 17, 43], ["catalytic site", "PROTEIN", 134, 148], ["binding sites", "PROTEIN", 184, 197], ["COVID-19", "DNA", 201, 209], ["SARS protease", "PROTEIN", 263, 276], ["proteases", "PROTEIN", 323, 332], ["enzyme binding site", "DNA", 455, 474], ["These changes", "PROBLEM", 0, 13], ["COVID", "TEST", 17, 22], ["protease sequence", "TEST", 26, 43], ["the different global architecture of protein", "PROBLEM", 56, 100], ["binding sites", "PROBLEM", 184, 197], ["COVID", "TEST", 201, 206], ["SARS protease", "PROBLEM", 263, 276], ["these two proteases", "TREATMENT", 313, 332], ["these changes in enzyme binding site", "PROBLEM", 438, 474]]], ["Table 1 represents the binding site residues for SARS and COVID-19 protease.", [["SARS", "DISEASE", 49, 53], ["COVID-19 protease", "GENE_OR_GENE_PRODUCT", 58, 75], ["SARS and COVID-19 protease", "PROTEIN", 49, 75], ["the binding site residues", "PROBLEM", 19, 44], ["SARS", "PROBLEM", 49, 53], ["COVID", "TEST", 58, 63]]], ["As it is evident there is only three residues similarity between two enzymes at positions 140-142 different amino acid constituent and geometry expectedly need different inhibitors with different stereochemistry.", [["amino acid", "CHEMICAL", 108, 118], ["amino acid", "CHEMICAL", 108, 118], ["amino acid", "AMINO_ACID", 108, 118], ["two enzymes", "TEST", 65, 76], ["different amino acid constituent", "TREATMENT", 98, 130], ["different inhibitors", "TREATMENT", 160, 180], ["different stereochemistry", "TREATMENT", 186, 211]]], ["Based on this fact it is necessary to search for different inhibitors for coronavirus, the investigation that is the main topic of this study.", [["coronavirus", "DISEASE", 74, 85], ["coronavirus", "ORGANISM", 74, 85], ["different inhibitors", "TREATMENT", 49, 69], ["coronavirus", "PROBLEM", 74, 85], ["the investigation", "TEST", 87, 104], ["this study", "TEST", 131, 141]]], ["In the next step, we carried out active site-directed docking of the selected ligands in ArgusLab software to study the binding capacity of ligands to fit the active site.", [["ArgusLab", "SIMPLE_CHEMICAL", 89, 97], ["active site", "PROBLEM", 33, 44], ["active", "OBSERVATION", 159, 165]]], ["The binding energies obtained from our docking our blind and active site-directed experiments are shown in table 2.", [["The binding energies", "PROBLEM", 0, 20], ["binding energies", "OBSERVATION", 4, 20]]], ["Pearson's two-tailed test of correlation was performed between blind and active site-directed docking reveals that there is no significant correlation between blind and site-directed energies (p-value >.05) and this means that the mechanisms underlie the interactions between ligand and protease is not the same and these two energies are completely independent variables and could be sums for comparative purpose.", [["protease", "PROTEIN", 287, 295], ["significant correlation between blind and site", "PROBLEM", 127, 173], ["p-value", "TEST", 193, 200], ["protease", "TREATMENT", 287, 295], ["no", "UNCERTAINTY", 124, 126]]], ["Based on our findings and as it is clear Tipranavir seems to be the most potent inhibitor for COVID-19 protease.", [["Tipranavir", "CHEMICAL", 41, 51], ["Tipranavir", "CHEMICAL", 41, 51], ["Tipranavir", "SIMPLE_CHEMICAL", 41, 51], ["COVID-19 protease", "GENE_OR_GENE_PRODUCT", 94, 111], ["COVID-19 protease", "PROTEIN", 94, 111], ["our findings", "TEST", 9, 21], ["Tipranavir", "TREATMENT", 41, 51], ["COVID", "TEST", 94, 99]]], ["Clinical trials reveal that Tipranavir is capable of viruses' replication in patients resistant to other protease inhibitors and resistance against this drug needs multiple mutations to take place simultaneously in protease genes [22] .IntroductionThe application of the drug in combination with one of the antiretroviral drugs as Ritonavir is approved for HIV-1 treatment by the FDA [23] .", [["Tipranavir", "CHEMICAL", 28, 38], ["Ritonavir", "CHEMICAL", 331, 340], ["Tipranavir", "CHEMICAL", 28, 38], ["Ritonavir", "CHEMICAL", 331, 340], ["Tipranavir", "SIMPLE_CHEMICAL", 28, 38], ["patients", "ORGANISM", 77, 85], ["Ritonavir", "SIMPLE_CHEMICAL", 331, 340], ["HIV-1", "ORGANISM", 357, 362], ["protease genes", "DNA", 215, 229], ["patients", "SPECIES", 77, 85], ["HIV-1", "SPECIES", 357, 362], ["HIV-1", "SPECIES", 357, 362], ["Clinical trials", "TEST", 0, 15], ["Tipranavir", "TREATMENT", 28, 38], ["viruses' replication", "TREATMENT", 53, 73], ["other protease inhibitors", "TREATMENT", 99, 124], ["this drug", "TREATMENT", 148, 157], ["multiple mutations", "PROBLEM", 164, 182], ["the drug", "TREATMENT", 267, 275], ["the antiretroviral drugs", "TREATMENT", 303, 327], ["Ritonavir", "TREATMENT", 331, 340], ["HIV-1 treatment", "TREATMENT", 357, 372]]], ["The second effective drug we introduced is Cefditoren, a cephalosporin antibiotic with broad-spectrum, administered for different conditions as pneumonia, acute bacterial and chronic bronchitis [24] [25] .", [["Cefditoren", "CHEMICAL", 43, 53], ["cephalosporin", "CHEMICAL", 57, 70], ["pneumonia", "DISEASE", 144, 153], ["acute bacterial and chronic bronchitis", "DISEASE", 155, 193], ["Cefditoren", "CHEMICAL", 43, 53], ["cephalosporin", "CHEMICAL", 57, 70], ["Cefditoren", "SIMPLE_CHEMICAL", 43, 53], ["cephalosporin", "SIMPLE_CHEMICAL", 57, 70], ["Cefditoren", "TREATMENT", 43, 53], ["a cephalosporin antibiotic", "TREATMENT", 55, 81], ["broad-spectrum", "TREATMENT", 87, 101], ["different conditions", "PROBLEM", 120, 140], ["pneumonia", "PROBLEM", 144, 153], ["acute bacterial and chronic bronchitis", "PROBLEM", 155, 193], ["pneumonia", "OBSERVATION", 144, 153], ["acute", "OBSERVATION_MODIFIER", 155, 160], ["bacterial", "OBSERVATION_MODIFIER", 161, 170], ["chronic", "OBSERVATION_MODIFIER", 175, 182], ["bronchitis", "OBSERVATION", 183, 193]]], ["Indinavir is the third effective inhibitor we candidate for COVID-19 treatment.", [["Indinavir", "CHEMICAL", 0, 9], ["COVID-19", "CHEMICAL", 60, 68], ["Indinavir", "CHEMICAL", 0, 9], ["COVID-19", "CHEMICAL", 60, 68], ["Indinavir", "SIMPLE_CHEMICAL", 0, 9], ["COVID-19", "SIMPLE_CHEMICAL", 60, 68], ["Indinavir", "TREATMENT", 0, 9], ["the third effective inhibitor", "TREATMENT", 13, 42], ["COVID-19 treatment", "TREATMENT", 60, 78]]], ["Considering the miscellaneous drugs available for HIV-1 treatment it is not currently recommended for HIV-1 treatment due to its side effects [26] .", [["HIV-1", "ORGANISM", 50, 55], ["HIV-1", "ORGANISM", 102, 107], ["HIV-1", "SPECIES", 50, 55], ["HIV-1", "SPECIES", 102, 107], ["HIV-1", "SPECIES", 50, 55], ["HIV-1", "SPECIES", 102, 107], ["the miscellaneous drugs", "TREATMENT", 12, 35], ["HIV-1 treatment", "TREATMENT", 50, 65], ["HIV-1 treatment", "TREATMENT", 102, 117], ["its side effects", "PROBLEM", 125, 141]]], ["However, it is shown that Indinavir by decreasing viral replication increases the life expectancy of the patient for several years in viral infections [27] .", [["Indinavir", "CHEMICAL", 26, 35], ["viral infections", "DISEASE", 134, 150], ["Indinavir", "CHEMICAL", 26, 35], ["Indinavir", "SIMPLE_CHEMICAL", 26, 35], ["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 105, 112], ["Indinavir", "TREATMENT", 26, 35], ["decreasing viral replication", "PROBLEM", 39, 67], ["viral infections", "PROBLEM", 134, 150], ["decreasing", "OBSERVATION_MODIFIER", 39, 49], ["viral replication", "OBSERVATION", 50, 67]]], ["The low water solubility of Indinavir requires plenty of water to dink to prevent its precipitation and crystallization as in kidneys [28] .IntroductionAtazanavir is the forth protease inhibitor that we recommend for COVID-19 infections.", [["kidneys", "ANATOMY", 126, 133], ["Indinavir", "CHEMICAL", 28, 37], ["Atazanavir", "CHEMICAL", 152, 162], ["infections", "DISEASE", 226, 236], ["Indinavir", "CHEMICAL", 28, 37], ["Atazanavir", "CHEMICAL", 152, 162], ["Indinavir", "SIMPLE_CHEMICAL", 28, 37], ["kidneys", "ORGAN", 126, 133], ["Atazanavir", "SIMPLE_CHEMICAL", 152, 162], ["The low water solubility of Indinavir", "TREATMENT", 0, 37], ["Atazanavir", "TREATMENT", 152, 162], ["the forth protease inhibitor", "TREATMENT", 166, 194], ["COVID-19 infections", "PROBLEM", 217, 236], ["low water solubility", "OBSERVATION_MODIFIER", 4, 24], ["kidneys", "ANATOMY", 126, 133]]], ["This inhibitor structural mimic the transition state of proteolysis at the Phe-Pro cleavage site.", [["Phe-Pro", "CHEMICAL", 75, 82], ["Phe-Pro cleavage site", "PROTEIN", 75, 96], ["This inhibitor", "TREATMENT", 0, 14], ["proteolysis", "PROBLEM", 56, 67], ["the Phe-Pro cleavage site", "TREATMENT", 71, 96]]], ["Atazanavir is prescribed for HIV-1 treatment in conjunction with an antiretroviral drug [29] .", [["Atazanavir", "CHEMICAL", 0, 10], ["Atazanavir", "CHEMICAL", 0, 10], ["Atazanavir", "SIMPLE_CHEMICAL", 0, 10], ["HIV-1", "ORGANISM", 29, 34], ["HIV-1", "SPECIES", 29, 34], ["HIV-1", "SPECIES", 29, 34], ["Atazanavir", "TREATMENT", 0, 10], ["HIV-1 treatment", "TREATMENT", 29, 44], ["an antiretroviral drug", "TREATMENT", 65, 87]]], ["Given that human proteases could not hydrolyze the Phe-Pro bonds so Atazanavir does not inhibit human proteases at all [30] [31] .", [["Phe-Pro", "CHEMICAL", 51, 58], ["Atazanavir", "CHEMICAL", 68, 78], ["Phe-Pro", "CHEMICAL", 51, 58], ["Atazanavir", "CHEMICAL", 68, 78], ["human", "ORGANISM", 11, 16], ["Atazanavir", "SIMPLE_CHEMICAL", 68, 78], ["human", "ORGANISM", 96, 101], ["human proteases", "PROTEIN", 11, 26], ["human proteases", "PROTEIN", 96, 111], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 96, 101], ["human proteases", "TREATMENT", 11, 26], ["Atazanavir", "TREATMENT", 68, 78], ["human proteases", "PROBLEM", 96, 111]]], ["The eighth drug we recommend for the clinical trial is Ritonavir which is a known inhibitor for HIV-1 protease.", [["Ritonavir", "CHEMICAL", 55, 64], ["Ritonavir", "CHEMICAL", 55, 64], ["Ritonavir", "SIMPLE_CHEMICAL", 55, 64], ["HIV-1 protease", "GENE_OR_GENE_PRODUCT", 96, 110], ["HIV-1 protease", "PROTEIN", 96, 110], ["HIV-1", "SPECIES", 96, 101], ["HIV-1", "SPECIES", 96, 101], ["Ritonavir", "TREATMENT", 55, 64], ["a known inhibitor", "TREATMENT", 74, 91], ["HIV", "PROBLEM", 96, 99]]], ["This inhibitor does not or rarely used alone for HIV-1 infectious and instead it is most often used in conjunction with other protease inhibitors to boost their antiviral action.", [["HIV-1 infectious", "DISEASE", 49, 65], ["HIV-1", "ORGANISM", 49, 54], ["HIV-1", "SPECIES", 49, 54], ["HIV-1", "SPECIES", 49, 54], ["This inhibitor", "TREATMENT", 0, 14], ["HIV", "PROBLEM", 49, 52], ["other protease inhibitors", "TREATMENT", 120, 145], ["their antiviral action", "TREATMENT", 155, 177], ["infectious", "OBSERVATION", 55, 65]]], ["Ritonavir itself inhibits liver and intestine enzymes that metabolize protease inhibitors and by the way, allows lower doses for these drugs to exert their effects [41] [42] [43] [44] .", [["liver", "ANATOMY", 26, 31], ["intestine", "ANATOMY", 36, 45], ["Ritonavir", "CHEMICAL", 0, 9], ["Ritonavir", "CHEMICAL", 0, 9], ["Ritonavir", "SIMPLE_CHEMICAL", 0, 9], ["liver", "ORGAN", 26, 31], ["intestine", "ORGAN", 36, 45], ["[41] [42] [43] [44]", "SIMPLE_CHEMICAL", 164, 183], ["liver and intestine enzymes", "PROTEIN", 26, 53], ["Ritonavir", "TREATMENT", 0, 9], ["liver and intestine enzymes", "TEST", 26, 53], ["metabolize protease inhibitors", "TREATMENT", 59, 89], ["these drugs", "TREATMENT", 129, 140], ["liver", "ANATOMY", 26, 31], ["intestine", "ANATOMY", 36, 45]]], ["The ninth drug seems useful for the clinical trial is Erythromycin the well known and safe antibiotic for respiratory tract infections and finally, Amprenavir is the tenth drug we recommend for a clinical trial for COVID-19Introductioninfections that have no vaccine and no approved drug with a reasonable rate of incidence and increasing percent of mortality [45] [46] .Conclusion:Our results indicate that there are structural differences between primary structures of proteases for COVID-19 contrasts to that's of SARS which leads to altered enzyme binding sites.", [["respiratory tract", "ANATOMY", 106, 123], ["Erythromycin", "CHEMICAL", 54, 66], ["respiratory tract infections", "DISEASE", 106, 134], ["Amprenavir", "CHEMICAL", 148, 158], ["SARS", "DISEASE", 517, 521], ["Erythromycin", "CHEMICAL", 54, 66], ["Amprenavir", "CHEMICAL", 148, 158], ["COVID-19", "CHEMICAL", 485, 493], ["Erythromycin", "SIMPLE_CHEMICAL", 54, 66], ["Amprenavir", "SIMPLE_CHEMICAL", 148, 158], ["COVID-19", "GENE_OR_GENE_PRODUCT", 485, 493], ["proteases", "PROTEIN", 471, 480], ["COVID", "PROTEIN", 485, 490], ["enzyme binding sites", "PROTEIN", 545, 565], ["Erythromycin", "TREATMENT", 54, 66], ["safe antibiotic", "TREATMENT", 86, 101], ["respiratory tract infections", "PROBLEM", 106, 134], ["Amprenavir", "TREATMENT", 148, 158], ["COVID-19Introductioninfections", "TREATMENT", 215, 245], ["vaccine", "TREATMENT", 259, 266], ["structural differences between primary structures of proteases", "PROBLEM", 418, 480], ["COVID", "TEST", 485, 490], ["SARS", "PROBLEM", 517, 521], ["altered enzyme binding sites", "PROBLEM", 537, 565], ["respiratory tract", "ANATOMY", 106, 123], ["binding sites", "OBSERVATION", 552, 565]]], ["We hypothesize that these alterations cause the enzyme, not to respond to anti-SARS protease inhibitors for treatment [47] [48] .Conclusion:During this work and via re-examining HIV-1 protease inhibitors and different anti bronchitis antibiotics we tried to find more effective inhibitors for COVID-19 treatment.", [["bronchitis", "DISEASE", 223, 233], ["COVID-19", "CHEMICAL", 293, 301], ["COVID-19", "CHEMICAL", 293, 301], ["anti-SARS protease", "GENE_OR_GENE_PRODUCT", 74, 92], ["HIV-1", "ORGANISM", 178, 183], ["COVID-19", "SIMPLE_CHEMICAL", 293, 301], ["HIV-1", "SPECIES", 178, 183], ["HIV-1", "SPECIES", 178, 183], ["the enzyme", "TEST", 44, 54], ["anti-SARS protease inhibitors", "TREATMENT", 74, 103], ["HIV-1 protease inhibitors", "TREATMENT", 178, 203], ["different anti bronchitis antibiotics", "TREATMENT", 208, 245], ["COVID-19 treatment", "TREATMENT", 293, 311]]], ["Finally, we picked up the following order for inhibitory potency among anti-HIV-1 protease inhibitors:Conclusion:Tipranavir>Indinavir>Atazanavir>Darunavir>Ritonavir>Amprenavir Similarly, the following order for anti bronchitis was obtainedCefditoren>Cefixime>Erythromycin>ClarithromycinConsidering this fact that all the drugs used in this study are approved by FDA for clinical application we hope that our findings considered for clinical trials in COVID-19 patients to overcome the world wide current outbreak of coronavirus.", [["Tipranavir", "CHEMICAL", 113, 123], ["Indinavir", "CHEMICAL", 124, 133], ["Atazanavir", "CHEMICAL", 134, 144], ["Darunavir", "CHEMICAL", 145, 154], ["Ritonavir", "CHEMICAL", 155, 164], ["Amprenavir", "CHEMICAL", 165, 175], ["bronchitis", "DISEASE", 216, 226], ["Cefditoren", "CHEMICAL", 239, 249], ["Cefixime", "CHEMICAL", 250, 258], ["Erythromycin", "CHEMICAL", 259, 271], ["Clarithromycin", "CHEMICAL", 272, 286], ["coronavirus", "DISEASE", 516, 527], ["Tipranavir", "CHEMICAL", 113, 123], ["Indinavir", "CHEMICAL", 124, 133], ["Atazanavir", "CHEMICAL", 134, 144], ["Darunavir", "CHEMICAL", 145, 154], ["Ritonavir", "CHEMICAL", 155, 164], ["Amprenavir", "CHEMICAL", 165, 175], ["Cefditoren", "CHEMICAL", 239, 249], ["Cefixime", "CHEMICAL", 250, 258], ["Erythromycin", "CHEMICAL", 259, 271], ["Clarithromycin", "CHEMICAL", 272, 286], ["anti-HIV-1", "GENE_OR_GENE_PRODUCT", 71, 81], ["Tipranavir", "SIMPLE_CHEMICAL", 113, 123], ["Indinavir", "SIMPLE_CHEMICAL", 124, 133], ["Atazanavir", "SIMPLE_CHEMICAL", 134, 144], ["Darunavir", "SIMPLE_CHEMICAL", 145, 154], ["Ritonavir", "SIMPLE_CHEMICAL", 155, 164], ["Amprenavir", "SIMPLE_CHEMICAL", 165, 175], ["Cefditoren", "SIMPLE_CHEMICAL", 239, 249], ["Cefixime", "SIMPLE_CHEMICAL", 250, 258], ["Erythromycin", "SIMPLE_CHEMICAL", 259, 271], ["Clarithromycin", "SIMPLE_CHEMICAL", 272, 286], ["patients", "ORGANISM", 460, 468], ["coronavirus", "ORGANISM", 516, 527], ["patients", "SPECIES", 460, 468], ["anti-HIV-1", "SPECIES", 71, 81], ["inhibitory potency", "TREATMENT", 46, 64], ["anti-HIV-1 protease inhibitors", "TREATMENT", 71, 101], ["Tipranavir", "TREATMENT", 113, 123], ["Indinavir", "TREATMENT", 124, 133], ["Atazanavir", "TREATMENT", 134, 144], ["Darunavir", "TREATMENT", 145, 154], ["Ritonavir", "TREATMENT", 155, 164], ["Amprenavir", "TREATMENT", 165, 175], ["anti bronchitis", "PROBLEM", 211, 226], ["Cefditoren", "TREATMENT", 239, 249], ["Cefixime", "TREATMENT", 250, 258], ["Erythromycin", "TREATMENT", 259, 271], ["Clarithromycin", "TREATMENT", 272, 286], ["the drugs", "TREATMENT", 317, 326], ["this study", "TEST", 335, 345], ["coronavirus", "PROBLEM", 516, 527]]]], "b914939a92682f82f1e778e19e143ac7bb5f129e": [["A fter imposing 15 d of nationwide social distancing and a \"stay-at-home\" order from April 1, 2020, to contain community transmission of the new coronavirus, Vietnam started seeing no daily new cases within its borders.", [["coronavirus", "DISEASE", 145, 156], ["coronavirus", "ORGANISM", 145, 156], ["the new coronavirus", "PROBLEM", 137, 156]]], ["This report is to share the country's roadmap to loosening social distancing restrictions so as to effectively controlling the COVID-19 situation and ensuring socio-economic development.REPORT Lifting of Social DistancingWhile most of the localities across the country are no longer classified as high-risk areas, specific districts, such as Me Linh and Thuong Tin in Hanoi, the capital of Vietnam, still remained on lockdown until May 14.", [["the COVID", "TEST", 123, 132], ["loosening", "OBSERVATION", 49, 58]]], ["The extension of lockdown was due to the last COVID-19 patients in these districts reported on April 15.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63]]], ["The normal operation of public and inter-provincial bus services, traditional taxis, and ride-hailing services has resumed since May 4.", [["normal", "OBSERVATION_MODIFIER", 4, 10], ["operation", "OBSERVATION", 11, 20]]], ["While hair and beauty salons reopened as early as on April 23, other nonessential services and businesses, such as restaurants, gyms, theaters, religious gatherings, and public gatherings of more than 30 people, continued to be suspended until May 8.", [["hair", "ANATOMY", 6, 10], ["hair", "MULTI-TISSUE_STRUCTURE", 6, 10], ["people", "ORGANISM", 204, 210], ["people", "SPECIES", 204, 210]]], ["On June 9, the Prime Minister of Vietnam agreed to resume karaoke parlors and nightclubs, although the specific reopening date will depend on each locality ( Figure 1 ).Resumption of Exports of Agricultural and Medical ProductsThe country's rice export sector has been adversely affected by the pandemic.", [["rice", "SPECIES", 241, 245], ["rice", "SPECIES", 241, 245], ["nightclubs", "TREATMENT", 78, 88], ["Agricultural and Medical Products", "TREATMENT", 194, 227]]], ["As the world's third largest rice exporter, Vietnam ordered a temporary suspension of rice exports while reviewing domestic inventories on March 24.", [["rice", "SPECIES", 29, 33], ["rice", "SPECIES", 86, 90], ["rice", "SPECIES", 29, 33], ["rice", "SPECIES", 86, 90], ["a temporary suspension of rice exports", "TREATMENT", 60, 98]]], ["It resumed rice exports with a quota raised to 400,000 metric tons for April, and subsequently allows normal rice exports from May 1.", [["rice", "SPECIES", 11, 15], ["rice", "SPECIES", 109, 113], ["rice", "SPECIES", 11, 15], ["rice", "SPECIES", 109, 113], ["a quota", "TREATMENT", 29, 36]]], ["2 There is a global shortage of medical face masks amidst the pandemic while domestic demand is met.", [["medical face masks", "TREATMENT", 32, 50], ["global", "OBSERVATION_MODIFIER", 13, 19], ["shortage", "OBSERVATION_MODIFIER", 20, 28]]], ["Therefore, in early April, the country's Prime Minister approved exports of medical products, such as face masks and protective clothing, to nations hardest hit by the pandemic.", [["medical products", "TREATMENT", 76, 92], ["face masks", "TREATMENT", 102, 112], ["protective clothing", "TREATMENT", 117, 136]]], ["3Health-care SystemIn the battle against COVID-19, the government of Vietnam's affordable and effective approach is to convert army camps, college and university dormitories, and hotels/resorts into centralized quarantine zones.", [["COVID", "TEST", 41, 46], ["Vietnam's", "TREATMENT", 69, 78]]], ["To prevent and control the spread of the disease in the community, Vietnam has endeavored to test anyone that may have had direct contact with infection sources.", [["infection", "DISEASE", 143, 152], ["the disease", "PROBLEM", 37, 48], ["infection sources", "PROBLEM", 143, 160], ["disease", "OBSERVATION", 41, 48]]], ["For example, if there is a confirmed case linked to local transmission, the patient must immediately undergo treatment at a provincial hospital while all direct contacts, referred to as F1, are required to test for COVID-19 and are sent to a quarantine zone.", [["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83], ["treatment", "TREATMENT", 109, 118], ["COVID", "TEST", 215, 220]]], ["Those, who have close contact with F1 need to be self-isolated.Health-care SystemCurrently, more than 110 laboratories across the country are able to conduct real-time polymerase chain reaction (PCR) tests for detection of the new coronavirus, with a total capacity of 27,000 samples per day.", [["coronavirus", "ORGANISM", 231, 242], ["PCR) tests", "TEST", 195, 205], ["the new coronavirus", "PROBLEM", 223, 242], ["a total capacity", "TEST", 249, 265], ["new", "OBSERVATION_MODIFIER", 227, 230], ["coronavirus", "OBSERVATION", 231, 242]]], ["As of April 30, approximately 261,000 tests had been performed, with 2684 tests per million people.", [["people", "ORGANISM", 92, 98], ["people", "SPECIES", 92, 98]]], ["4Current SituationAs of June 18, the country has documented 342 positive cases of COVID-19, with 325 of these having recovered.", [["COVID", "TEST", 82, 87]]], ["And though there have been 74 new infected cases over the past 60 d, these are Vietnamese returnees mostly from the United Arab Emirates and Russia, and were quarantined upon arrival.", [["new infected cases", "PROBLEM", 30, 48], ["new", "OBSERVATION_MODIFIER", 30, 33], ["infected", "OBSERVATION_MODIFIER", 34, 42], ["cases", "OBSERVATION", 43, 48]]], ["No new locally acquired cases have been recorded in the country since April 16.", [["new locally acquired cases", "PROBLEM", 3, 29], ["new", "OBSERVATION_MODIFIER", 3, 6], ["locally", "OBSERVATION_MODIFIER", 7, 14]]], ["Hence, it ponders an end of the pandemic in the country.", [["pandemic", "OBSERVATION", 32, 40]]], ["Nevertheless, the country still needs to encourage its citizens to use face masks, frequently wash hand, stay vigilant, and avoid complacency.DISCUSSIONNotably, Vietnam prudently allowed the normal operation of public transportation and taxi services to resume in the week following the country's National Reunification and International Labor Days (ie, April 30 and May 1).", [["hand", "ANATOMY", 99, 103], ["hand", "ORGANISM_SUBDIVISION", 99, 103], ["face masks", "TREATMENT", 71, 81]]], ["The explanation for this resumption is to help prevent possible massive passenger transport and public gatherings during the holidays, minimizing potential risks of spreading COVID-19.", [["massive passenger transport", "PROBLEM", 64, 91], ["spreading COVID", "TEST", 165, 180]]], ["Despite hammering the tourism industry, the travel restrictions have shown effectiveness in preventing travel-related infection cases and local spread of the disease.", [["infection", "DISEASE", 118, 127], ["infection cases", "PROBLEM", 118, 133], ["the disease", "PROBLEM", 154, 165], ["infection", "OBSERVATION", 118, 127], ["local", "OBSERVATION_MODIFIER", 138, 143], ["spread", "OBSERVATION_MODIFIER", 144, 150], ["disease", "OBSERVATION", 158, 165]]], ["Recently, early detection and quarantine have been recognized as being more effective in alleviating this pandemic than travel restrictions.", [["quarantine", "TREATMENT", 30, 40]]], ["6 The country requires that all people entering the country by means of air, sea, or land undergo medical checks and 14-d quarantine at government-run facilities upon arrival to effectively contain local transmission of the new coronavirus.", [["coronavirus", "DISEASE", 228, 239], ["people", "ORGANISM", 32, 38], ["coronavirus", "ORGANISM", 228, 239], ["people", "SPECIES", 32, 38], ["medical checks", "TEST", 98, 112], ["the new coronavirus", "PROBLEM", 220, 239]]], ["7, 8 Unlike repatriation by means of air, returnees by means of land borders, particularly Cambodia, may not always enter the country legally, 9 making it difficult to contain COVID-19.", [["COVID-19", "CHEMICAL", 176, 184], ["COVID", "TEST", 176, 181], ["air", "OBSERVATION", 37, 40]]], ["To prevent and control this situation, local authorities need to work in coordination with local people and relatives of illegal returnees.DISCUSSIONVietnam's tourism sector, which plays an important role in the country's economic development, appears to be hard hit by the pandemic.", [["people", "ORGANISM", 97, 103], ["people", "SPECIES", 97, 103]]], ["Fear and anxiety about the disease at the early stage of the COVID-19 outbreak in January caused tourism to plummet in Vietnam.", [["anxiety", "DISEASE", 9, 16], ["Fear", "PROBLEM", 0, 4], ["anxiety", "PROBLEM", 9, 16], ["the disease", "PROBLEM", 23, 34]]], ["10 The easing of social distancing measures has set the stage for the return of 11 However, it is prudent to not currently reopen doors to foreign tourists, as the COVID-19 situation in the world is rapidly evolving and can be hardly foreseeable, hinting at the high risk of another outbreak.CONCLUSIONSIn summary, while many parts of the world are still on lockdown amidst the pandemic, Vietnam has lifted social distancing restrictions and is rebooting its socio-economic activities.", [["social distancing measures", "TREATMENT", 17, 43], ["the COVID", "TEST", 160, 169]]], ["Meanwhile, exports of agricultural and anti-COVID-19 medical products and promotion of domestic tourism are prioritized.", [["agricultural and anti-COVID-19 medical products", "TREATMENT", 22, 69], ["domestic tourism", "OBSERVATION", 87, 103]]]], "096797c22e471cc23384fd840a53cc6a0f454529": [["We urge all countries to acknowledge the Italian lesson and to immediately adopt very restrictive measures to limit viral diffusion, ensure appropriate health-system response, and reduce mortality, which Green dots are for countries with more than 2 weeks of lag time from Italy; orange is for countries with 1-2 weeks of lag time; and red is for countries with 1 week or less of lag time.", [["Green dots", "ORGANISM", 204, 214], ["very restrictive measures", "TREATMENT", 81, 106], ["viral diffusion", "PROBLEM", 116, 131]]]]}